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ABSTRACT: 
The ability to make multiplexed measurements has significantly improved our 
understanding of disease onset and progression.  This newfound understanding has the potential 
to transform clinical diagnostics.  Also known as personalized medicine, diagnostic decisions are 
improved by relying on a detailed knowledge of an individual’s biochemical signature.  While 
routine clinical tests detect one biomarker at a time, new technologies are needed that enable the 
analysis of multiple targets per clinical sample.   
This doctoral dissertation presents a platform that can complete these goals by developing 
assays that combing enzymatic processing steps with silicon photonic microring resonators, a 
technology pioneered by the Bailey Research Laboratory.  While other efforts in lab have been 
geared to other classes of biomolecules, the developed assays discussed in this dissertation are 
designed to profile nucleic acid biomarkers in a host of clinically relevant samples.  The results 
from these studies are confirmed using clinical gold standard techniques and compared with 
findings in the literature to validate the platform. 
Chapter 1 discusses how silicon photonic microring resonators fit into the landscape of 
next-generation multiplexed biomolecular detection platforms while also developing the 
motivation to use enzymatic processing of nucleic acids to produce ultra-sensitive detection 
platforms.  Chapter 2 gives an exhaustive review of current microRNA (miRNA) detection 
platforms, both clinical gold standards and emerging technologies.  Given the unique detection 
challenges of microRNAs, this class of RNA molecule was used to develop a detection platform 
which could then be translated to other RNA molecules.  Chapter 3 describes the use of 
enzymatic processing of miRNA sequences and subsequent on-chip enzymatic signal 
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enhancement strategy to lower the required input of RNA material to a clinically relevant 
amount.  Chapter 4 outlines further improvements to enzymatic pre-processing of miRNA 
molecules by interfacing an adapted polymerase chain reaction process with the microring 
platform to study miRNA expression in glioblastoma patients.  It also eliminates the need for on-
chip signal amplification.  Chapter 5 adapts this workflow and uses it for the detection of long-
noncoding RNA (lncRNA) molecules in a previously uncharacterized glioblastoma cell line.  
Chapter 6 outlines additional research efforts and future directions, which include efforts to build 
a platform combining enzymatic pre-processing with microring resonator detection and efforts to 
push into an expanded set of clinical and research applications where low sample inputs and 
short analysis times are needed. 
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Chapter 1 
 
INTRODUCTION TO MULTIPLEXED ANALYSIS AND 
THE SILICON PHOTONIC MICRORING RESONATOR 
PLATFORM 
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1.1 Motivation for Multiplexed Analysis 
Personalized, or precision, diagnostics has been fueled by the concept that early detection 
of disease would benefit patients.  This early detection would make tumors easier to resect and 
treatments more effective.  Technological advances enabling the ability to view and understand 
an individual’s biomolecular signatures have revolutionized clinical diagnostics and have begun 
to make personalized medicine a reality.  While the discussion here will be limited to genomics 
and transcriptomics, the same trends can also be said for protein-based biomarkers as well.
1
 
The advent of the polymerase chain reaction in the 1980s gave researchers the ability to 
analyze genetic differences between multiple samples.
2,3
  A couple of years later, scientists took 
this idea and combined it with the semiconductor industry to create nucleic acid microarrays,
4,5
 
which, combined with the completion of the Human Genome Project,
6
 facilitated gene profiling 
studies that allowed researchers to compare the genetic differences between healthy individuals 
with those who developed specific disease states.
7
  These discoveries motivated the development 
of next-generation sequencing technologies, and now we are able to sequence an individual’s 
genome at a cost approaching $1,000. 
With the cost of these genetic testing technologies decreasing, the ability to place them in 
the clinic becomes more and more attainable.  However, new technologies are needed to realize 
the potential of genetic testing in clinical settings.  The two clinical gold standards, quantitative 
polymerase chain reaction (qPCR) and next generation sequencing (NGS), serve two opposite 
functions.  qPCR focuses on the analysis of one target per sample but makes it reasonably easy to 
analyze the expression of that target from multiple samples.  On the other hand, NGS enables the 
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analysis of all genetic material from a sample, but one cannot analysis multiple patient samples 
easily.  With it becoming clearer that multiplexed panels of 10s-100s of gene targets have the 
ability to identify predisposition to various disease types
8
 and in some instances can better 
diagnose patients and identify the optimal therapeutic regimens,
9
  new technologies are needed 
the void between the single-plex nature of qPCR and the lower throughput of NGS as shown in 
Figure 1.1. 
1.2 Next Generation Technologies for Meso-plex Diagnostics 
Recently, researchers have begun to fill the void by developing meso-plex diagnostic 
instrumentation.  These solutions take form using a variety of transducers to make measurements 
and have shown moderate success in a host of diseases.  In order to be clinically viable, detection 
platforms must have the following attributes:  (1) the ability to profile low sample inputs, (2) 
good efficiency, (3) easy to use, (4) the ability to multiplex, (5) high degree of reproducibility, 
and (6) the ability to selectively detect the correct biomolecule.
10
  While there are numerous 
examples in the literature, commonly discussed meso-plex instrumentation can be organized in 
the following two groupings: solution-phase fluorescent based instrumentation and array based 
surface-detection methodologies, like nuclear resonance, refractive-index, electrochemistry, etc. 
New platforms based on fluorescent transducers take place in many shapes, either 
focusing on detecting fluorescent beads or fluorescent barcodes functionalized to a recognition 
biomolecule.  In the first case, microparticles are coated with a recognition element, i.e. antibody 
or complimentary nucleic acid sequence.  These coated microparticles are then incubated with a 
sample of interest and washed.  Fluorescent dye functionalized molecules specific to the bound 
analyte molecules are then added to the sample well and allowed to bind.  After another washing 
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step, this solution is then ready using scanning instrumentation.  This technology is being 
commercialized by Singulex.  Initially the scanning instrumentation was similar to that of flow 
cytometry, but recently they have introduced a second generation technology that can make the 
measurement straight from the sample well.
11
  Additionally, while simple, this technology has 
limited multiplexing capabilities due to the use of fluorescent dyes.  A recent study incorporated 
multiple excitation lasers to measure the expression of three proteins from a sample volume, but 
even with this innovation multiplexing capabilities are limited by the spectral overlap of the 
fluorescent dyes.
12
  Figure 1.2 outlines the basic schematic of this technology as well as attempts 
to multiplex. 
A variation to this technique aims to increase multiplexing capabilities and is being 
commercialized by Luminex.  This assay also relies on sandwich assays but increases 
multiplexing capabilities by using two fluorescent beads.  The first bead used to capture the 
target of interest contains differing concentrations of a fluorescent dye.  This bead contains a 
specific concentration of dye that is related to the capture probe on the surface.  Therefore 
different fluorescent intensities of this dye can be related to a specific capture probe and target, 
thus enabling multiplexed measurements.  After the analytes are allowed to bind, the second 
fluorescent dye functionalized biomolecule is allowed to bind.  This dye is measured by the 
scanning instrumentation and related to the presence, or concentration, of the target molecule.  
Figure 1.3 shows the mechanism of detection and sandwich assay formation for proteins and 
nucleic acids as well as the scanning and detection protocol. 
While Luminex makes these measurements in bulk solution, Quanterix has developed a 
similar platform based on nanowell arrays  Here, they use fluorescent magnetic beads to capture 
specific proteins using a sample dilution where on average there will be at most one analyte 
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molecule per bead. Following this step, a sandwich assay is formed with an enzyme 
functionalized antibody after incubation with a sample of interest.  The beads are then captured 
in a nanowell array and an activatable fluorescent substrate is added.  If the analyte is present, it 
is detected via the fluorescent signal of the substrate that is turned over in the presence of the 
enzyme on the sandwich complex. The scanning instrumentation then determines which analyte 
is present based on the florescent signal of the bead in the nanowell.
13
  Figure 1.4 outlines the 
detection process as well as shows initial efforts aimed to multiplexed.  This is achieved by using 
a fluorescent-dye functionalized capture bead.  The fluorescent signal from the capture bead is 
this associated with the recognition molecule on the surface and the presence of the activated 
fluorescent molecule is associated with the target biomolecule.
14
 
The last fluorescent platform (commercialized by Nanostring Technologies) also utilizes 
sandwich assays, but instead of using a concentration gradient like the Luminex platform, 
conjugates multiple fluorophores together to create a fluorescent barcode specific to each gene 
(see Figure 1.5).
15
  While mainly used for the detection of nucleic acid sequences, this platform 
has also been adapted for protein expression analysis.
16
  While each of the discussed fluorescent 
assays show respectable figures of merit and facilitate solution phase detection, they either suffer 
from complex fluorophore conjugation steps, long time to results, poor reproducibility, and 
inherent limitations in multiplexing capabilities through spectral overlap of fluorescent dyes.   
In an effort to avoid the inherent multiplexing challenges of fluorescent moieties, array 
based technologies have also been engineered to facilitate for multiplexed biomolecular 
profiling.  An example of this type of technology relies on magnetic bead aggregation in the 
presence on a target biomolecule which induces a shift in the NMR spectrum (commercialized 
by T2 Biosystems).  This assay has been used to quickly determine protein expression in human 
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tissues
17
 as well as determine the phenotype of bacteria in clinical settings,
18
 as shown in Figure 
1.6.  Current generations of this technology match the muliptlexing capabilities of most 
fluorescent based systems (4-8 targets).  Additionally, there are multiple examples of various 
microarray and modified well plate arrangements that rely on chemiluminescence and 
electrochemical detection but they will not be discussed here.  Most array based technologies 
suffer from the same drawback that sample volumes need to be aliquoted into different channels 
or reaction wells for detection because the signal transducer cannot distinguish the differing 
targets in the same sample volume. 
1.3 Introduction to the Theory and Operation of Silicon Photonic Microring Resonators 
The Bailey Lab has focused on developing a microresonator-based waveguide sensor 
platform, part of a larger class of whispering gallery mode sensors,
19,20
 for the meso-plex 
detection of biomolecules, which build upon the shortcomings of previously discussed 
technologies.  First, this planar, array based technology takes advantage of traditional 
semiconductor fabrication techniques to easily fabricate cost effective sensor arrays with 132 
sensors per chip measuring 3 x 4 mm at a scale necessary for eventual clinical placement.  
Second, with 132 sensors on a sensing chip numerous biomolecules can be studied per sample 
volume and chips can be run in parallel to easily profile numerous patient samples.  Third, this 
technology detects changes in refractive index to determine solution phase concentration of 
biomolecules.  Refractive index based sensing removes the need to rely on any fluorescent tags 
or enzymes.   
The mechanism of this technology is included in Figure 1.7.  To start, a tunable laser is 
swept through an appropriate spectral window.  The laser output is coupled into linear 
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waveguides via on-chip grating couplers.  The light propagates down the waveguides via total 
internal reflectance.  Only specific wavelengths of light couple into the microring structure, as 
defined by the following equation: 
mλ = 2πneff 
where m is an integer, λ is the wavelength of light, r is the radius of the ring, and neff is the 
effective refractive index of the environment surrounding the sensor.  When this resonance 
condition is not met, all light that is coupled onto the chip then reaches the detector after being 
coupled off chip via another set of downstream grating couplers.  This is reflected by no decrease 
in the transmission of light as shown in Figure 1.7B.  When the resonance condition is met, the 
specific wavelength is supported by the microring cavity and optical interference occurs between 
the cavity and the linear waveguide, which prevents the wavelength of light from reaching the 
detector.  This is reflected in a decrease in transmission. 
As governed by the equation above, changes in the local refractive index surrounding the 
microring surface changes the wavelength supported by the microring resonator.  This detection 
platform utilizes this to detect biomolecular binding near the ring surface.  When biomolecular 
binding occurs, the event displaces water which changes neff and thus the wavelength.  The 
magnitude of biomolecular binding and resulting and shift in resonant wavelength is ultimately 
related to the solution phase concentration of the biomolecule of interest. 
1.4 Introduction RNA Biomarker Detection and Motivation of Thesis Work 
The overarching goal of my dissertation work is to develop a multiplexed assay that can 
detect multiple classes of RNA from clinically relevant samples.  While the Bailey Lab has 
previously developed a universal ultra-sensitive protein detection protocol
21
 and is using it in a 
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host of clinical applications, the same cannot be said for nucleic acids.  To date, assays 
developed in lab have focused on specific RNA types instead of developing an assay for all 
nucleic acid classes. 
The progression of RNA detection over the years has focused on lowering LODs by 
adding mass tags to the microring surface to amplify the signal response, as summarized in 
Figure 1.8.  In 2010, Qavi et al. were able to detect direct hybridization of four miRNA targets to 
covalently bound capture probes on the microring resonator surface.  This assay took only 15 
minutes to complete, but suffered from required total RNA input of 300 μg which precludes its 
use in the clinic.
22
  In 2011, Qavi et al. attempted to increase the sensitivity of the platform by 
incorporating a way to amplify the signal response after hybridization of the microRNA target.
23
  
They accomplished this by using an antibody recognizing RNA:DNA heteroduplexes.  Upon 
antibody binding to the miRNA target:DNA capture probe heteroduplex, it significantly 
increases the mass bound to the sensor surface thus amplifying the original hybridization signal 
which leads to lower input amounts required.  In this case, this signal amplification strategy 
lowered the input amount from 300 μg to 50 μg, which is still larger than the input required for 
clinical gold standard techniques where the required input ranges from 1 μg to 1 ng.  Similar to 
the S9.6 strategy, Kindt et al. developed an amplification protocol using streptavidin coated 
nanoparticles and biotin functionalized chaperone DNA sequences to detect mRNA sequences.
24
  
This protocol further reduced total RNA requirements to 20 μg, which is still higher than the 
stated goal of 1 μg or less.  Furthermore, these examples provide the proof of concept studies to 
detect no more than four target sequences per sample.   
The overarching goal of my dissertation is three fold (1) to develop a RNA detection 
assay using input amounts of 1 μg or less, (2) to create an assay that can profile multiple classes 
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of RNA, and (3) increase multiplexing capabilities of previously established techniques 
developed in the lab.  Progress toward achieving these goals was accomplished by using 
enzymatic amplification processes, and the following chapters outline the progression.  Chapter 2 
motivates the need for better technologies to detect microRNAs.  Chapters 3 and 4 outline efforts 
to develop improved microRNA detection protocols.  Chapter 5 builds on the work presented in 
Chapter 4 by utilizing the same detection platform to analyze the expression of long non-coding 
RNA sequences.  Lastly, Chapter 6 outlines avenues of where to take this technology into the 
future and ultimate placement in the clinic. 
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1.5 FIGURES 
 
Figure 1.1:  Graph showing the void in current technologies.  These technologies either focus on 
analyzing the expression of one biomolecule in multiple samples (qPCR) or on analyzing the 
expression of all biomolecules present in one sample (microarrays in next-generation 
sequencing).  This void is being filled with novel meso-plex detection methods that are able to 
detect the expression of multiple biomolecules in multiple samples. 
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Figure 1.2: Schematic of the Singulex platform.
12
 (A) Overview of the detection mechanism, 
including sandwich assay formation and the solution phase single molecule imaging.  Image 
reproduced from www.singulex.com. (B) Image of the multi-excitation and detection wavelength 
set up to facilitate multiplexed detection using the Singulex platform.  Reproduced from Gilbert, 
M; Livingston, R.; Felberg, J.; Bishop, J.J. Analytical Biochemistry 2016, 503, 11-20 (ref 12). 
Copyright 2016 Elsevier. 
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Figure 1.3: Schematic of Luminex platform.
25,26
 (A) Mechanism of sandwich assay formation 
for both protein and nucleic acid targets.  The key development of this platform is the use of 
capture beads with a varying concentration of a fluorophore.  Reproduced from Dunbar, S.A.; 
Vander Zee, C.A.; Oliver, K.G.; Karem, K.L.; Jacobson, J.W. Journal of Microbiological 
Methods 2003, 53, 245-252 (ref 23). Copyright 2003 Elsevier. (B) Mechanism of target 
detection.  Two fluorophores are imaged, with one related to the specific capture probe used and 
the other related to the presence or absence of the analyte.  Two version of the detection 
instrumentation are used.  Reproduced from Spierings, G. Methods in Molecular Biology 2013, 
1015, 115-126 (ref 24). Copyright 2013 Springer. 
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Figure 1.4: Schematic of the Quanterix platform.
13,14
 (A) This figure goes through the detection 
and quantitation of target analytes.  Reproduced from Rissin, D.M.; Kan, C.W.; Campbell, T.G.; 
Howes, S.C.; Fournier, D.R.; Song, L. Nature Biotechnology 2010, 28, 595-599 (ref 13) 
Copyright 2013 Nature Publishing Group.  (B) This image outlines the ability to multiplex by 
using fluorescent functionalized fluorescent capture beads.  Reproduced from Rissin, D.M.; Kan, 
C.W.; Song, L.; Rivnak, A.J.; Fishburn, M.W.; Shao, Q.; Piech, T.; Ferrell, E.P.; Meyer, R.E.; 
Campbell, T.G.; Fournier, D.R.; Duffy, D.C. Lab on a Chip 2013, 13, 2902-911 (ref 14). 
Copyright Royal Society of Chemistry. 
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Figure 1.5: Schematic of the Nanostring platform.
15
 Key to this schematic is the use of a target-
specific fluorescent tag shown in A and B.  Reproduced from  Kulkarni, M.M. Current Protocols 
in Molecular Biology, 2011, 94, B.10.1-B.10.25  (ref 15). Copyright 2011 John Wiley & Sons. 
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Figure 1.6: Schematic of T2 Biosystems microNMR platform.
17,18
 (A) Example of tumor sample 
analysis using by aggregation of nanoparticles induced by the expression of cell surface proteins.  
Modest multiplexing capabilities were shown by using four discrete channels within the mini-
magnet.  Reproduced from Haun, J.B.; Castro, C.M.; Wang, R.; Peterson, V.M.; Marinelli, B.S.; 
Lee, H.; Weissleder, R. Science Translational Medicine 2011, 3, 1-13 (ref 16). Copyright 2011 
American Association for the Advancement of Science. (B) Example of nucleic acid detection 
based on the aggregation of capture beads and magnetic nanoparticles.  Reproduced from Chung, 
H-J.; Castro, C.M.; Im, H.; Lee, H.; Weissleder, R. Nature Nanotechnology, 2013, 8, 369-375 
(ref 17). Copyright 2013 Nature Publishing Group. 
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Figure 1.7: Schematic of Genalyte microring resonator detection platform. (A) Renderings of 
the chip layout, the internal optics of the instrumentation, and the instrumental set up in lab. (B) 
Outline of the microring resonator detection theory. 
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Figure 1.8: Overview of previous RNA detection schemes developed in the Bailey Lab. (A) 
Label-free, direct detection schemes for DNA and microRNA.
22,27
  Reproduced from Qavi, A.J.; 
Bailey R.C. Angewandte Chemie International Edition 2016, 49, 4608-4611 (ref 20) and Qavi, 
A.J.; Bailey R.C. Analytical Chemistry 2011, 83, 6827-6833 (ref 25).  Copyright 2011 American 
Chemical Society. (B) Scheme for the detection of microRNA using an antibody as a mass tag to 
lower limits of detection.
23
  Reproduced from Qavi, A.J.; Kindt, J.T.; Bailey R.C. Analytical 
Chemistry 2011, 83, 5949-5956 (ref 21). Copyright 2011 American Chemical Society. (C) 
Developed assay for the detection of mRNA using a bead as a mass tag to amplify the microring 
response and thus lower limits of detection.
24
 Reproduced from Kindt, J.T.; Bailey, R.C. 
Analytical Chemistry 2012, 84, 8067-8074 (ref 22). Copyright 2012 American Chemical 
Society.  
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Chapter 2 
 
EMERGING BIOSENSING APPROACHES FOR 
MICRORNA ANALYSIS 
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2.1 Introduction 
2.1.1 Background and Relevance 
 Since their discovery more than two decades ago in C. elegans,
1
 microRNAs (miRNAs) 
have emerged as an important class of non-protein coding RNA molecules. miRNAs serve as 
critical gene expression regulators at the transcriptional and post-transcriptional level and are 
widely conserved across a broad range of animals, plants, and viruses. Landmark studies have 
associated miRNAs with key biological events like developmental timing in C. elegans
2
 and 
zebrafish
3
 and cancer development in humans.
4
 These studies along with many others that have 
established miRNA control over numerous biological processes would not have been possible 
without reliable miRNA detection methods. The impact that these analytical tools have had is 
reflected in the rapid increase in publications that focus on “miRNA detection”, as shown in 
Figure 2.1. The aim of this review is to outline the current state of the art while also highlighting 
exciting new biosensing approaches to miRNA detection that might help realize the full potential 
of miRNA expression profiles in both the contexts of fundamental biology studies and clinical 
diagnostics.  
microRNAs are short, non-coding RNAs that are roughly 22 nucleotides in length. 
miRNA sequences regulate the expression of mRNA targets with either perfect complementarity, 
which leads to mRNA degradation, or imperfect complementarity, which often results in 
repression of translation. While the biogenesis of miRNA has been previously reviewed,
5-7
 the 
basic process of miRNA expression and maturation is outlined in Figure 2.2. The genesis of 
miRNAs is in the nucleus where primary miRNA transcripts (pri-miRNA) are produced. The pri-
miRNA sequence is cleaved by the Drosha-DGCR8 complex to produce a pre-miRNA hairpin. 
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This precursor hairpin is then transported to the cytoplasm via Exportin-5-Ran-GTP. In the 
cytoplasm, the Dicer processing complex cleaves the pre-miRNA hairpin to the mature sequence. 
One strand of the mature miRNA, the guide strand, is loaded into the miRNA-induced silencing 
complex (RISC), which contains DICER1 and Argonaute proteins, and directs the RISC to target 
mRNA sequences. This miRNA directed process affects gene expression through mRNA 
cleavage, translational repression, or deadenylation.
5,6
 It is important to note that it is valuable 
for analytical methodologies to discriminate between pri-, pre-, and mature forms of miRNA 
sequences. 
miRNA regulation ultimately results in altered protein levels and can have profound 
consequences on cellular homeostasis. In fact, miRNA expression profiling has identified a host 
of regulated biological processes, including immune response
8
, cell differentiation,
9,10
 and cell 
proliferation and death.
11
 Furthermore, if the miRNA regulatory machinery that governs these 
processes is interrupted, it becomes extremely important to identify these disruptions and 
understand how they evolve as disease drivers. For example, Rosenfeld and co-workers showed 
how patterns of aberrantly expressed miRNAs could differentiate between tissues of origin 
across multiple cancer types.
12
 Once changes in miRNA expression are better understood in a 
biological context (i.e. what induces specific upregulation and down regulation patterns), they 
can then be used as potential therapeutic targets as well as refined into improved diagnostic 
biomarker panels.
13
  
Recent work aimed at understanding how changes in miRNA expression can lead to 
specific disease states has shown promise. Initial efforts have implicated aberrant miRNA 
expression with cancer, 
14
 neurological disorders,
15,16
 diabetes,
17
 and cardiovascular disease,
18,19
 
to name just a few. Equally promising is the fact that the detection of these biopanels is not 
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limited to tissue. A host of studies have shown the ability to detect miRNA biopanels in a variety 
of biofluids. For example, Weber and co-workers were able to identify meaningful miRNA 
profiles found in twelve different biofluids, including cerebrospinal fluid, blood, serum, saliva, 
and urine.
20
 As increasing attention is focused on non- or minimally-invasive diagnostic 
methods, the presence of freely circulating miRNA profiles provides a promising approach to 
disease monitoring. Other studies have again established disease-correlated miRNA levels in 
blood;
21,22
 however the tools for detection and interpretation of the biological significance of 
these alterations in expression must still be refined in order to achieve full clinical adoption and 
translation.  
2.1.2 miRNA Profiling Challenges 
While the clinical and biological implications of altered miRNA expression are being 
elucidated, progress remains to be achieved in the development of robust analytical technologies 
that facilitate routine miRNA analysis. Improved techniques will help realize the impact that 
miRNA profiling can have on understanding disease onset and progression, and may play a key 
role in the realization of personalized medicine. In order to provide improved miRNA detection 
modalities, one must first understand the analytical challenges that miRNA’s present and the 
importance of sample processing and miRNA isolation. 
Analytical Challenges 
There are many unique characteristics of microRNAs that pose analytical challenges for 
their accurate detection and quantification.  The most important of these characteristics are their 
small size and thermodynamic considerations, sequence similarity, wide range in abundance, and 
their ability to regulate multiple targets.
23,24
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  The small size of miRNAs presents specific thermodynamic considerations and makes 
their analysis more difficult than the significantly longer mRNAs. Due to their small length, the 
GC content variation in miRNA sequences leads to a wide range of melting temperatures (Tm). 
Since the vast majority of miRNA detection methods rely on some sort of hybridization step, this 
can introduce sequence-specific bias. Additionally, the small size of miRNAs, roughly the same 
size a traditional primer, complicates the use of the polymerase chain reaction (PCR). 
 In addition to thermodynamic constraints, there are additional difficulties that complicate 
the analysis of miRNAs, as compared to mRNAs, due to the very nature of their seuqence. For 
example, miRNAs lack the poly(A) tail of mRNAs, which is often used as a universal primer for 
reverse transcription or selective pre-enrichment. This is especially important as miRNAs make 
up roughly 0.01% of total RNA extracted from a sample of interest.
25
 This means that any 
bioanalysis platform must be able to differentiate small amounts of miRNA in the presence of a 
large abundance of total cell RNA. Moreover, the abundance of particular miRNA sequences can 
vary from single copies to more than 50,000 copies in a single cell,
26
 thus requiring exceptional 
dynamic range. Finally, families of miRNAs are often expressed differing only by single 
nucleotides and so extremely high sequence selectively is a necessity.  
 Beyond specificity, selectivity, and large dynamic range, it is also important that 
analytical methods for miRNA detection allow for multiplexed analysis, whereby levels of more 
than one miRNA are quantitated simultaneously and from a single sample. This analytical 
requirement is important on account of the biological mode of action of miRNAs. A single 
miRNA sequence is capable of regulating up to hundreds of different mRNA sequences and a 
single mRNA can be targeted by many different miRNAs. Therefore, in order to fully 
comprehend the biological significance of miRNAs in both health and disease, one must be able 
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to analyze the ensemble effects of miRNA expression changes and understand the interrelated 
consequences on multiparametric regulatory networks that extend across all levels of 
biomolecular information (i.e. DNA, mRNA, miRNA, and proteins). To this end, it is becoming 
increasingly clear through both experimental results and computational modeling
27,28
 that the 
creation of multiplexed miRNA panels is needed to deconvolute these complex interactions. 
Sampling Considerations 
It is also worth noting that the reproducibility of experimentally-determined miRNA 
expression profiles is directly related to the ability to isolate high quality RNA samples. It is 
possible to isolate miRNAs from cell lines, fresh and formalin fixed paraffin embedded (FFPE) 
tissue, and various bodily fluids.
20,29
 Interestingly, while mRNA often suffer from RNase 
degradation, particularly in FFPE samples, miRNA have been shown to be more stable.
30,31
 
Given some of the aforementioned challenges of miRNA analysis compared to mRNAs, the 
greater stability of miRNAs in a diverse set of sample matrices provides an opportunity to 
expand their utility through the study of large libraries of archived tissue and blood samples. 
Generally, most workflows to isolate RNA from a sample follow the same procedure,
31
 
using phenol/chloroform purification with chaotrophic salts (i.e. guanidinium thiocynate) to 
denature RNases and proteins associated with RNAs. After centrifugation, nucleic acids partition 
into the aqueous and interphase while proteins partition into the organic phase.  The RNA from 
the resulting aqueous phase is then bound to a solid phase silica column and washed. To isolate 
the small RNA fraction from total RNA, diluted ethanol can be used which will cause large 
RNAs to dissociate from the silica column and leaves purified small RNAs (<200 nucleotides) in 
the final elution volume. Finally, the RNA molecules are eluted off the column and analyzed for 
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purity, using UV-Vis spectroscopy, and integrity, using the band intensity ratio of the 28S to 18S 
rRNA bands measured using gel or capillary electrophoresis.  Low integrity samples containing 
fragmented RNA suffer from a higher background of small RNA sequences, which then leads to 
lower quality miRNA profiling data with a higher chance of off-target responses. 
2.1.3 Scope 
It is clear that miRNAs play incredibly important roles in biology; however, many gains 
remain in the translation of this fundamental insight into the clinical setting. Key to this 
achievement will be the development of robust and multiplexed analytical technologies that offer 
strategic advantages over conventional techniques, such as qRT-PCR, microrarrays, and RNA-
sequencing. Motivated by the aforementioned analytical challenges, this review focuses on the 
recent demonstrations of new microRNA detection platforms, with particular emphases placed 
on reports published since 2013. At the forefront of promising approaches are advanced 
biosensor technologies. Beyond a discussion of conventional approaches and emerging 
techniques, we also provide commentary and perspective regarding the role of bioinformatics in 
constructing multiplexed miRNA panels, as well as how future advances might impact the 
clinical adoption of panel-based miRNA diagnostics. 
2.2 Conventional Methods 
Three major approaches are used at present to determine levels of miRNA expression: (1) 
reverse transcription-quantitative polymerase chain reaction (qRT-PCR), (2) hybridization-based 
microarrays and (3) next generation high-throughput sequencing. This section provides details on 
each as a way of providing context for the development of emerging biosensing technologies. 
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2.2.1 Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) 
 Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) is the current 
gold standard for miRNA analysis. It is commonly used to detect levels of single or small, 
targeted panels of miRNAs and also to validate selected results from more global expression 
studies (i.e. microarrays and next generation sequencing, as described in subsequent sections). 
qRT-PCR analysis provides a large dynamic range, inherent sensitivity through the ability of 
PCR to selectively amplify specific target sequences, lower assay costs compared to next 
generation sequencing, and the ability to measure multiple miRNAs by running reactions in 
parallel (normally in 96 or 384 well plates). The major downside to running parallel reactions is 
higher consumption of the sample of interest, qRT-PCR consumables, and enzymes/master 
mixes. As mentioned earlier, the short size of miRNAs complicates all PCR-based detection 
schemes due to similarities between the length of the target and primer. However, two of the 
more common strategies to achieve this goal are: (1) reverse transcription via stem loop primers 
and the use of TaqMan PCR, and (2) enzymatic addition of a poly(A) tail to RNAs followed by 
reverse transcription and SYBR Green based qPCR detection.
30
 The overall workflow for both of 
these qRT-PCR approaches are illustrated in Figure 2.3A. 
 Stem loop primers are designed to contain a 6-8 nucleotide overhang on the 3’ end that is 
complimentary to a region of the targeted miRNA and can differentiate between closely related 
sequences as well as different miRNA forms (i.e. pri-, pre-, and mature).
32
 Upon hybridization 
between the stem loop primer and the target miRNA, reverse transcription extends the DNA 
compliment of the hybridized miRNA from its 3’ end. The use of stem loop primers facilitates 
better specificity by optimizing the melting temperature and effectively lengthens the miRNA 
target, so that the RT product can then be recognized by a standard PCR primer set. The RT-
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extension step is typically performed at temperatures <16°C to preserve the secondary structure 
of precursor miRNA sequences. PCR amplicons are then generated using a miRNA-specific 
forward primer that binds to the 3’ end of the reverse transcription (RT) product and a universal 
reverse primer that binds to the conserved stem loop region of all RT products. Additionally, a 
molecular beacon, or TaqMan, probe is present in the PCR reaction solution and is designed to 
hybridize in between the forward and reverse primers. As the DNA polymerase proceeds along 
the template and reaches the TaqMan probe, the probe is hydrolyzed and the fluorescent dye is 
freed from the quencher, resulting in an emission signal proportional to the total amount of PCR 
product produced. This signal, measured as a function of cycle number, is then used to determine 
the overall level of a specific miRNA in a sample. 
The poly(A) method involves the 3’ polyadenylation of all RNA in a sample normally 
using either polyadenylate polymerase or T4 ligase. When T4 ligase is used, an additional 
sequence can be installed following the poly(A) tail that further lengthens the downstream RT 
product to enable binding of the two PCR primers. After the poly(A) tail addition, binding of a 
poly(dT) DNA primer, which serves as the reverse transcription primer, initiates the RT reaction 
and production of cDNA. Conventional PCR primers are then added to initiate amplification, and 
PCR product formation is measured using a dsDNA-intercalating SYBR green dye.  
 The main drawback of qRT-PCR is complex primer design requirements and the inability 
to analyze multiple targets per single sample volume. The design of both RT and PCR primers 
vary substantially between miRNA targets due to differences in Tm between the resulting primer-
target duplexes. However, this problem can be partially alleviated through the use of Tm-
matched locked nucleic acid primer sequences.
33
 It also remains difficult to measure multiple 
miRNAs from within a single qRT-PCR reaction volume, as qPCR is limited by its reliance on 
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spectral multiplexing. Run-to-run inconsistencies due to variability in PCR amplification 
efficiencies is also a complication that requires careful design of internal controls, which often 
require the use of global mean averaging,
34
 referencing common housekeeping genes,
35
 the 
spiking in of non-natural miRNA probes that are added before the RNA extraction step,
36
 or 
some combination of these control methods.
37
 
2.2.2 Microarrays 
Originally developed in the early 1990s for genomic-scale analysis of DNA, microarrays 
were redeployed as one of the first methods applied to the global analysis of miRNA 
expression.
30,38
 Typically, miRNAs are first labeled with a fluorescent reporter.  This is 
accomplished by dephosphorylating the 5’ end of the miRNA followed by ligation of a 
fluorescently tagged oligonucleotide or short oligonucleotide strand using T4 ligase.  The 
dephosphorylation of the 5’ end is critical to prevent self-circularization of the miRNA and 
adapter sequences.
39
  The functionalized miRNA is then introduced to the array surface where 
they hybridize to complimentary DNA (cDNA) capture probes immobilized on a glass slide, 
followed by two channel fluorescent imaging, which can provide expression levels. As a result of 
being a surface-bound hybridization based assay, microarrays require complimentary base-paring 
between the cDNA:miRNA. The overall workflow for microarray-based analysis of miRNAs is 
shown in Figure 2.3B. 
Despite the relative ease and historical utility of DNA microarrays, there are some 
limitations in their application to miRNAs, particularly in light of competing methods.
31
 For 
instance, they are only semi-quantitative due to the absence of a calibration curve from the 
experimental workflow. As a result, microarrays are best used when comparing miRNA 
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expression levels between multiple states (i.e. heathy vs. disease). To ensure specificity, 
microarrays also often require additional validation, which often is achieved via qRT-PCR for 
select targets of interest. Microarrays also suffer have a smaller dynamic range than both qRT-
PCR and next generation sequencing. 
Despite these drawbacks, microarrays do offer the advantage of being cheaper than 
global profiling via next generation sequencing. Additionally, substantial effort has already been 
invested in the development of Tm-normalized cDNA capture probes that incorporate peptide 
nucleic acids
40
 and locked nucleic acids.
41
 The thermal stability of hybridization duplexes across 
the array can lead to reproducible results and assays with high sensitivity. Other studies have 
aimed to improve the fluorescent labeling step of the microarray workflow to reduce non-
specific background signal. These improvements have focused on the use of labeled binding 
proteins that only binds to miRNA molecules hybridized at the surface,
42
 a hybridization based 
labeling technique termed stacking-hybridized-universal-tagging (SHUT) that allows for the 
addition of one universal tag,
43
 and a ligase-assisted sandwich hybridization based approach that 
eliminates the need for miRNA labeling by ligating a signal probe that binds to capture 
probe:miRNA hybrids at the array surface.
44
 The sandwich hybridization based assay improved 
hybridization efficiency 50,000-fold and allowed quantitation of a synthetic miRNA sequence 
down to 30 fM. Beyond this limited discussion, other developments in miRNA-detecting 
microarrays have recently been reviewed.
31,45
  
2.2.3 Next-Generation Sequencing 
The advent of next generation sequencing (NGS) platforms has enabled a third major 
approach for miRNA expression profiling, and, with continuing decreases in sequencing cost, 
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this is quickly becoming a dominant method applied to the analysis of miRNAs. The 
technologies driving NGS has been reviewed.
46,47
 While the procedures vary depending on 
specific platform, the first step involves the preparation of a small cDNA library from the RNA-
containing sample of interest using a reverse transcription process similar to qRT-PCR. Adaptors 
are ligated to both the 5’ and 3’ ends of the cDNA products, and the resulting products are 
attached to either a planar or bead based substrate.  This is followed by the massively parallel 
sequencing of millions of individual cDNA molecules from the library. Bioinformatic analysis of 
the sequence reads trims the adaptor sequences off of the miRNA sequences.  The trimmed 
sequences are then aligned against a miRNA sequence data base (ex. miRBase) to identify the 
known miRNAs present in the sample.  This sequence data also provides quantification by 
identifying the number of sequence reads present. Unique to miRNA analysis is the ability for 
bioinformatic approaches to identify novel miRNA sequences that are not already annotated in 
miRNA databases by attempting to align to precursor miRNA sequences.  This presents a unique 
set of advantages as well as roadblocks that must be solved to continue to expand the use of next 
generation sequencing for miRNA profiling.  The overall work for the NGS workflow applied to 
miRNA analysis is outlined in Figure 3.3C. 
The major advantage of NGS for miRNA analysis is the ability to obtain a truly global 
expression profile. In addition to known sequences, which could be detected using a pre-
synthesized cDNA microarray, previously unknown short RNA sequences can be discovered de 
novo. Sequencing also obviates the concerns with specificity faced by hybridization-based 
methods, including qRT-PCR, microarrays, and the majority of the biosensor-based approaches 
described below. To gain clinical traction, overall sequencing costs, including reagents, still need 
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to be driven down further. Also, streamlined informatics techniques are needed to simplify 
and/or automate data analysis for use in clinical settings.  
The quality of using NGS for miRNA expression profiling in clinical samples has been 
analyzed in recent publications that compare the results obtained using RNA-sequencing to both 
qRT-PCR and microarrays.
48,49
 One study found discrepancies between platforms that were 
attributed to differences in normalization protocols as well as potential sampling biases.
48
 The 
other, though, revealed strong correlation between RNA-seq and qRT-PCR.
49
 This report also 
showed good correlation between expression levels from flash-frozen and FFPE samples, which 
is important for analysis of current and archived clinical samples. Additional studies validating 
RNA-seq and other conventional analysis methods are important and needed to help put into 
perspective the vast literature reporting miRNA expression results obtained by different 
platforms and, ideally, may result in the identification of clinically-useful miRNA based tests. 
Given the breadth of expression data provided by NGS-based miRNA analysis it is 
reasonable to consider that most of the resulting information will not be informative in the 
context of human health and disease. Moreover, an infomatically-robust panel of miRNAs might 
be extracted from global data sets and correlated with different diagnostic or prognostic 
outcomes.
50,51
 Therefore, the workflow by which RNA-seq can be used to identify and translate 
multiplexed miRNA panels to cost effective biosensing technologies remains an important goal. 
Once promising panels of miRNAs are proposed, cheaper and less time consuming technologies 
might be a better fit for high throughput analyses, as well as eventual use in the clinical setting.  
Going forward, NGS will, if it has not already, become the preferred technique for global 
miRNA expression profiling and novel sequence identification that establishes correlations with 
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disease. Subpanels may then be informatically-selected and then validated and translated to the 
clinic using the emerging technologies described in the following section. 
2.2.4 Summary of Conventional miRNA Analysis Methods 
qRT-PCR, microarrays, and next generation sequencing have all played key roles in 
advancing our knowledge as to how miRNAs play key roles in regulating gene expression and in 
beginning to translate this fundamental insight to application in clinical diagnostics. A high level 
comparison of the attributes of each of these general classes of techniques is presented in Table 
2.1. However, these technologies face critical hurdles to achieve widespread clinical adoption 
that justify the development of emerging biosensing technologies. qRT-PCR methods are 
incredibly sensitive, relatively rapid, and cost effective; however they can only measure levels of 
one miRNA per assay, thus requiring multiple sample aliquots to profile a panel of targets, which 
is prohibitive for sample-limited specimens. Microarrays are exceptionally well-suited to 
multiplexed analyses, but are typically slow, less sensitive, and minimally-quantitative. Next 
generation sequencing technologies are also well-suited to give a global analysis of all miRNAs 
present in a sample, but require complex processing steps, an even longer time-to-result, and can 
present challenges with back end informatics. Therefore, there exists a pressing need for the 
development of multiplex diagnostic capabilities whereby focused panels of 10s of miRNAs can 
be simultaneously interrogated using rapid, cost effective, and highly scalable technologies. Such 
technologies would have broad-reaching utility in both basic and clinical research and be 
applicable to both tissue and biofluid-based diagnostic applications. 
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2.3 Biosensor Methods 
miRNAs have been a focus of biosensor development over the past decade, with many 
micro- and nanoscale sensing technologies being applied to this class of analytes. Benefits of 
many of these schemes lie in their potential for diagnostics at the point of care. However, it is 
important to point out that for many diagnostic needs, analyses performed in a central laboratory 
over the multi-hour-to-day timeframe are completely acceptable for many applications, such as 
in the diagnostic or longitudinal monitoring of relatively slowly progressing  diseases, such as 
cancer. Coupled with these devices have been a number of novel signal transducers, 
incorporation of modified nucleic acid capture sequences, and the development of new signal 
amplification strategies. The past few years have shown a movement away from proof-of-
principle technology demonstrations and an increasing emphasis on obtaining the sensitivity and 
sequence selectivity required for clinical applications. A number of reports have also explored 
low levels of multiplexing; however, most of these studies only analyze 2-3 sequences at a time. 
Here, we focus broadly on some of the most recent reports considering promising optical, 
electrochemical/electrical, and magnetoresistive technologies for miRNA detection, emphasizing 
improvements to analytical sensitivity and selectivity and highlighting some of the more 
promising demonstrations of multiplexing.  
2.3.1 Optical Detection 
A wide range of optical detection methods have been applied to miRNA detection. 
Fluorescent dyes and quantum dots directly conjugated to nucleic acids detection probes have 
been widely explored in FRET-based analyses and also coupled with enzymatic methods for 
enhanced performance. In these examples, multiplexing must typically be achieved spectrally, 
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which places some constraints on the number of sequences that can be simultaneously assayed. 
Electrochemiluminescent assays have also been developed that offer promising enzyme- and 
nucleic acid-based signal enhancement strategies. Surface-tethered optical methods based on 
plasmons or waveguide properties promise higher levels of multiplexing through the creation of 
spatially-resolved sensor arrays, but th ese measurements are constrained to binding on sensor 
surfaces.  
FRET and related approaches 
 To improve upon microarrays, which most commonly require labeling of the miRNA 
before detection, fluorescent assays today aim to use fluorescent reporters that bind to the 
miRNA target via a detection probe. To provide the appropriate specificity, strategies have been 
designed to ensure that the fluorescent signal is “off” with no miRNA signal is present and “on” 
when the target is present. Forster resonance energy transfer (FRET) is a common approach to 
facilitate “on/off” detection schemes. An overview of different FRET-based miRNA detection 
methods is provided in Figure 3.4. 
A simple, but effective, FRET approach used a DNA strand-displacement scheme, where 
fluorescently tagged DNA capture probes were initially hybridized with a quencher 
functionalized compliment. When present, the target miRNA displaced the quenching strand and 
turned “on” the fluorescent signal. This approach was used to detect the presence of 3 miRNA 
sequences across multiple cell lines with an LOD of 1 fM and a dynamic range of 4 orders of 
magnitude.
52
 Despite its simplicity, the main drawback of this approach is the false positive rate, 
whereby closely related species might displace the quenching strand giving an erroneous result. 
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Molecular beacons aim to improve specificity by incorporating a fluorescent tag on one 
end of the sequence and a fluorescent quencher on the other, thus creating a FRET pair on a 
single capture sequence. With no miRNA present, the strand adopts a thermodynamically stable 
hairpin geometry with the fluorophore in close proximity to the quenching molecule. Upon 
hybridization of a target miRNA, the beacon linearizes, causing separation of the fluorophore 
and quencher and turning “on” the fluorescence.53 The opposite scheme has also been developed 
where a molecular beacon was created that was initially held “open” via an interaction with a 
reporter sequence that featured multiple base pair mismatches. In this case, the fluorophore and 
quencher started off spatially separate, and the presence of the miRNA of interest displaced, 
allowing the beacon to fold on itself turning “off” the fluorescent signal.54 This simplified assay 
took only could be run in as little as 10 minutes and achieved better specificity by using locked 
nucleic acid detection strands. However, the limit of detection (LOD) was limited to 10 nM. 
Greater multiplexing capabilities of this molecular beacon-FRET approach were achieved with 
quantum dots, due to their increased brightness and inherent color tunability. Here, three 
miRNAs were detected in diluted serum without the need for any washing steps, and a LOD of 1 
nM was reported.
55
   
While the aforementioned molecular beacon approaches achieved nanomolar LODs, 
different FRET pairs have shown improved assay performance. Graphene oxide was used as a 
quencher, where fluorescently tagged miRNA compliments were absorbed onto the surface.
56
 In 
the presence of the miRNA target, the capture probe was released and hybridized with the target, 
generating a fluorescent signal. Further improvements to specificity were made by incorporating 
peptide nucleic acids into the molecular beacon sequence absorbed onto the graphene oxide 
surface.
57
 Improved performance was also achieved by using DNA probes that were 
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approximately three times larger than the miRNA target, thus offering a higher affinity for 
adsorption onto the substrate and effectively eliminating non-specific desorption of the 
fluorescent nucleic acid sequence.
58
  The target binds a region of the capture probe and an 
exonuclease cleaves the DNA:miRNA hybrid from the quenching substrate turning “on” the 
fluorescent signal. LODs as low as 3 fM were reported; however, multiplexing capabilities were 
not investigated. 
While the simplicity of FRET based assays provide many advantages for in vitro 
diagnostics, they also can facilitate the quantitative profiling of miRNA expression in vivo. For 
example, a duplex DNA FRET probe was used to detect the intracellular presence of miRNA-
294, a marker for neuronal cell differentiation,
59
 and a molecular beacon approach allowed for 
imaging of miRNA-126 as a general marker for ischemia.
53
 Another interesting development 
involved a single stranded FRET probe that was delivered into cells, where it bound to the 
complimentary miRNA, and was loaded into the RISC complex. The FRET probe was then 
hydrolyzed and liberated the fluorescent reporter, allowing the detection of miR-10b, a 
metastatic marker associated with breast cancer.
60
 Ryoo, et.al. described an approach with 
graphene oxide as the quenching substrate used to simultaneously detect the presence of 3 
miRNA in living cells.
61
 A similar approach employed carbon nitride nanosheets as a quencher.
62
 
While these devices are able to identify the presence of miRNA targets in living cells, these 
workflows ultimately suffer from poor sensitivity and a limited dynamic range.  
The aforementioned FRET-based strategies were stoichiometric, that is a single miRNA 
molecule led to a single fluorophore being turned “on” or “off”. In order to achieve better signal 
gain, several target recycling strategies have been reported by which a single miRNA can lead to 
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the generation of fluorophore signals per sequence. Several promising target recycling strategies 
are highlighted schematically in Figure 3.5. 
Duplex-specific nuclease (DSN), and enzyme that recognizes and selectively cleaves the 
DNA strand from a DNA:miRNA duplex was employed to detect miRNA, resulting in the 
release of either a fluorophore or a DNA strand to induce a detectable signal. After cleavage of 
the DNA, the miRNA is free to bind to another DNA capture sequence and the DSN process is 
repeated. In this way, a single miRNA strand can interact with thousands of reporter sequences 
giving high levels of signal gain.  This general strategy has been broadly incorporated into a 
wide variety of optical detection assays, including a fluorescently-tagged molecular beacons,
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DNAzyme capture probes,
64
 graphene oxide quenching assays,
65
 WS2 quenching assays,
66
 
magnetic beads,
67
 gold nanoparticle quenching assays,
68
 and gold nanoparticle aggregation 
assays.
69
 A great example showing the potential of the DSN assay was shown by Yin and co-
workers, who designed a simple FRET-based strategy that allowed three miRNA sequences to be 
simultaneously detected down to 1 fM across a dynamic range close to 5 orders of magnitude.
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Other target regeneration strategies utilized toehold-mediated recycling and nickase 
based recycling. In both of these approaches, after target recycling the capture probes are 
introduced to the sample of interest and when the miRNA is present it either linearizes upon 
hybridization
71
 or dissociates from a quenching substrate.
72
 These techniques eliminate the need 
for fluorescent dye conjugated directly capture probes by staining the hybrid product with an 
intercalating fluorescent dye. This strategy achieved picomolar detection limits and a dynamic 
range of 3-4 orders of magnitude.  The nickase based strategy immobilized the target miRNA on 
a graphene oxide substrate to protect from RNases. A stem loop primer was then introduced and 
hybridized with the miRNA target, which caused desorption of the miRNA from the graphene 
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oxide.  Exponential amplification was then achieved in the presence of a DNA polymerase 
through target recycling using a nicking enzyme.  The resulting dsDNA products were stained 
with an intercalating fluorescent dye. The intercalating dye approach has the advantage of having 
multiple fluorescent dyes per target rather than only a single fluorophore conjugated to a single 
capture probe, giving a LOD of 11 fM and 3 order of magnitude dynamic range.
73
 Of course the 
limitation of the intercalating dye approach is that the dye will stain any nucleic acid duplex 
without the sequence specificity that can be engineered using covalently attached fluorophores 
conjugated to specific strands. Another nickase based recycling approach relied on the formation 
of a three way junction consisting of the target miRNA sequence, an assistant DNA probe, and 
an Hg
2+
 intercalated molecular beacon. Upon complex formation, the intercalated Hg
2+
 was 
liberated and able to quench the fluorescent signal from the linearized molecular beacon.
74
 This 
approach gave a detection limit of detection of 0.16 nM and a dynamic range of 3 orders of 
magnitude. 
Electrochemiluminescence 
Like fluorescence, electorchemiluminescence (ECL) can be used to produce a detectable 
optical signal that is proportional to the miRNA concentration in a sample. ECL is an alternative 
approach to lamp or laser based excitation, where an electrochemical excitation can create a 
luminescent response in the presence of an ECL reporter molecule. This flexible excitation 
approach, which generally turns “on” response, does not require the use of specific wavelength 
lasers to selectively excite a fluorescent dye. Additionally, these approaches often show exquisite 
sensitivity due to the elimination of background fluorescent interfering species in solution. As an 
example of an ECL-based approach to detect miRNAs, a sandwich hybridization approach was 
successfully used to profile a single miRNA in three cell lines.
75
 Without any sample recycling 
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or signal amplification, this strategy produced an LOD of 100 pM and a dynamic range of 
approximately 3 orders of magnitude. While these numbers are respectable, signal amplification 
strategies can be invoked to further increase limits of detection, improve specificity, and extend 
dynamic range. 
Variations of the hybridization chain reaction and enzymatic amplification can both be 
utilized for eletrochemiluminescent signal amplification. The hybridization chain reaction allows 
for a dramatic increase in dsDNA length that is catalyzed in the presence of a target miRNA. 
This allows for various ECL co-reactants, such as [Ru(phen)3]
2+
 
76
 and hemin-conjugated 
DNAzymes,
77
 to intercalate into the resulting duplex. The LODs for these techniques were 1 and 
1.7 fM, respectively, with linear dynamic range of 4 orders of magnitude. 
Enzymatic amplification strategies have been deployed using rolling circle amplification to 
form DNAzymes,
78
 cyclic exponential amplification recycling,
79
 doxorubicin conjugated 
quantum dots,
80
 T7 exonuclease recycling and downstream silver deposition,
81
 ECL quenching 
via Phi29 DNA polymerase mediated strand displacement,
82
 and a dual target amplification 
strategy with combined ECL and fluorescence detection.
83
 With one exception, all of these 
strategies report LODs ranging between 10 fM and 100s of aM with dyamic ranges varying 2-5 
orders of magnitude. The stand displacement system reported a remarkable detection limit of 3.3 
aM and a dynamic range of 5 order of magnitude.
82
 Importantly, none of these examples 
demonstrated multiplexing capacity, likely in part due to the fact that ECL reporter molecules are 
not specific to an individual miRNA sequence, similar to that described above for the 
intercalating dye systems. 
Plasmonic and Photonic Approaches 
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While fluorescence based detection has the benefit of enabling detection in free-solution, it 
is ultimately limited by the fact that a label is required for detection. Likewise, there are a fixed 
number of labels (i.e. fluorescent dyes or FRET pairs) that are easily detected with unique, non-
overlapping signatures, which limits multiplexing capabilities. Additionally, it is often difficult 
remove excess fluorescent reporter sequences from solution if a FRET pair is not used, creating a 
large amount of background signal. In the case of electrochemiluminescence, multiplexing 
capabilities are difficult due to the need for multi-electrode arrays that can require unique 
potentiostatic control, and the fact that many ECL reporter molecules are not specific to an 
individual miRNA sequence. As alternatives that capture the spatial multiplexing features of 
traditional microarrays, methods that detect surface-hybridization through changes in optical 
properties, such as refractive index in the case of surface plasmon resonance (SPR) and other 
approaches, have grown in popularity. These techniques can often be operated in label-free 
sensing modes or combined with different enhancement strategies to further improve analytical 
performance metrics. 
 In addition to established label free detection modalities, such as conventional 
Kretschmann geometry surface plasmon resonance
84
, other sensing mechanisms have been 
explored for applications in miRNA analysis, including nano-particle scattering on flexible 
silicon substrates,
85
 surface enhanced Raman spectroscopy,
86
 functionalized gold nanoprisims 
attached to silanized glass,
87
 Mach-Zehender interferometers,
88
 and total internal fluorescence 
microscopy.
89
 An impressive gold nanowire plasmonic based detection mechanism was 
developed as a microfluidic lateral flow assay. A detection limit of 100 aM was achieved for a 
bi-temperature sandwich based hybridization scheme. The cDNA-modified gold nanowire was 
incubated at a low temperature to ensure specific base pairing with a target miRNA  in solution, 
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followed by an elevated temperature exposure to a LNA functionalized presenting a Cy5 moiety 
that was detected via its surface-enhanced Raman scattering signal.
90
 This strategy showed the 
multiplexing capacity to detect 4 miRNAs simultaneously over a dynamic range of six orders of 
magnitude. A schematic representation of this detection method is shown in in Figure 2.6A. 
Additional label free miRNA sensors aimed to improve upon previously outlined 
weaknesses. For instance, to avoid diffusion limitations experienced by surface based 
measurement modalities, a solution-based stem loop primer-functionalized plasmonic 
nanoparticle aggregation assay was developed. Upon hybridization of the target, the plasmon 
resonance shifts due to a change in distance between nanoparticles in the aggregate. The 
magnitude of this shift can then be related to the solution phase concentration.
91
 The LOD of this 
assay is 10s of fM; however, the dynamic range was limited to a single order of magnitude.  
In an effort to achieve point-of-care miRNA detection, Gao and co-authors developed a 
lateral flow nanoparticle aggregation assay. Hybridization of a miRNA to cDNA-modified 
particles produced a visual colorimetric change on account of nanoparticle aggregation in less 
than 20 minutes.
92
 To increase sensitivity, a next generation sensor was developed that used 
nanoparticles conjugated to horseradish peroxidase that, in a subsequent step, catalyzed the 
oxidation of TMB to produce a blue product. This amplification step improved the limit of 
detection from 60 pM to 7.5 pM.
93
 A potential drawback is the lack of multiplexing capabilities 
as different targets would require parallel detection using separate devices or channels. 
Techniques like traditional Kretschmann geometry SPR and SPR imaging have 
previously been applied to the detection of miRNAs; however, when operated in label-free 
assays, limits of detection are only modest, as the small size of a captured miRNA does not cause 
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a large change in refractive index at the sensor surface. To improve upon these detection limits, 
several label-included signal amplification strategies have been developed. Many of these 
approaches involve a high mass recognition element that can recognize and bind directly to the 
cDNA:miRNA duplex at the sensor surface. A simple example is that of Vaisocherova and 
coworkers, where a DNA functionalized nanoparticle recognized half of a miRNA sequence 
where the other half will be bound to an SPR sensor, forming a conventional sandwich complex. 
Using this approach, illustrated in Figure 2.6B, they demonstrated a 4-plex assay for miRNA 
detection in cell lysate with a LOD of 0.5 pM.
94
 Another approach used biotin-streptavidin 
interactions to engender a 24-fold increase in detection sensitivity.
95
  Lastly, an alternative 
method used DSN and monitored the decrease in signal over time as the cDNA strand was 
displaced from the surface. Importantly, the miRNA released from the SPR chip surface can 
rebind to other cDNAs thereby effectively recycling the target. This assay gave a detection limit 
of 3 fM and could differentiate miR-21 concentrations in total RNA solutions extracted from the 
blood of a variety of cancer patients.
96
  
Two notable non-plasmonic, photonic detection technologies have also recently shown 
promise for miRNA analysis. Cunningham and co-workers have pioneered the development 
photonic crystals for biosensing applications and have demonstrated their applicability to the 
detection of miRNAs. Photonic crystals were engineered to enhance the fluorescence signal of 
tagged miRNA sequences hybridized to a cDNA capture probes on the sensor surface.
97
  Due to 
the localization of the electric field the fluorophores experience during excitation and enhanced 
signal extraction of the fluorophore emission through coupling to modes of the photonic crystal, 
signal gains of more than 8,000 were reported.  This sensor was used to quantitate the expression 
of miRNA-21 and achieved a 0.1 pM LOD.  It is also interesting that the ability to quantitate 
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both miRNA and proteins using the same sensing modality.  In attempts to cut down the volume 
needed to complete analysis, the fluorescence enhanced photonic crystal approach was adapted 
to a submicron fluid channel.
98
  This hybridization based assay was dependent on miRNAs 
binding with molecular beacons functionalized at the photonic crystal surface.  Using the 
narrower channel geometry, only 20 nL of sample was needed to complete analysis. 
Silicon photonic microring resonators have also been demonstrated for the detection of 
miRNAs, 
99
 
100
 as well as full length mRNAs.
101
  A simple detection scheme was developed by 
monitoring direct hybridization of miRNA targets to DNA capture probes on the photonic ring 
resonator surface.
99
 The binding event caused a change in refractive index, which, in turn, 
created a detectable change in resonant wavelength that can be related to the concentration of the 
target of interest.  Using this approach, it took ten minutes to simultaneously profile four 
miRNAs, and an LOD of 2 nM was reached.  To improve the sensing attributes of the platform, a 
RNA:DNA heteroduplex specific antibody, S9.6, was used.
100
  After miRNA:DNA capture 
probe hybridization, the antibody was introduce to the sensor surface and allowed to bind.  The 
added mass of the antibody at the sensor surface caused a larger shift in the resonance 
wavelength due to a larger change in the refractive index close to the sensor surface.  This 
resulted in improvements to the LOD of over 2 orders of magnitude (10 pM) and a dynamic 
range over 4 orders of magnitude.  Impressively, this assay was able to quantitate four miRNA 
simultaneously from total RNA isolated from mouse brain tissue. 
2.3.2 Electrochemical Detection 
Electrochemical sensors are well-established for a number of classes of target analytes, 
and obvious successes, such as the portable glucose meter, have established their capabilities for 
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simple, rapid, and low cost bioanalysis. Not surprisingly, there has been considerable growth in 
the area of electrochemical biosensors for miRNA. Given the requirement for making 
measurements at a solid electrode, electrochemical miRNA biosensors are typically based on 
hybridization at the electrode surface, and similar to plasmonic and photonic optical sensors, can 
be operated in label free and label-enhanced assay formats. As discussed below, detection is 
commonly achieved through the measurement of a redox signal or a change in capacitance or 
impedance. 
Label-free approaches to electrochemical detection 
Label free detection assays are the simpliest electrochemical measurement schemes, 
relying only upon target hybridization to a surface-bound capture probe. An example of this 
strategy involved a novel carbon nanofiber functionalized screen printed electrode functionalized 
with a capture probe having electrochemically-inactive inosine in place of guanine. 
Hybridization of the miRNA target then generated a detectable guanine oxidation peak that was 
measured using differential pulse voltammetry with a detection limit of 1.5 μM.102 However, in 
comparison with other techniques, the sensitivity of this assay can be greatly improved.  
Alternative electrode materials have resulted in significantly improved sensitivity. For 
instance, a RNA duplex specific binding protein, p19, was immobilized on an electrode surface 
and only when an RNA duplex was present was a signal due to tryptophan oxidation detected. 
The LOD of this assay was reported at 160 nM.
103
 Carbon nanotube functionalized glassy carbon 
electrodes were used to increase guanine oxidation current density by a factor of ~3 over 
conventional glassy carbon electrodes, achieving a LOD of 1 pM.
104
 Another method involved 
using a quinone based conducting polymer as a redox transducer on a functionalized electrode 
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surface. Differential currents were detected based on the orientation of the DNA capture probe—
collapsed on the surface in the absence of the target, yet linear and lifted off the electrode when 
hybridized to the target miRNA, allowing for more efficient diffusion of counter-ions to the 
surface. Here, the electrode material had a large influence on the sensitivity, where an LOD of 
650 fM was obtained using a glassy carbon electrode
105
 and 8 fM for a carbon nanotube 
functionalized electrode.
106
 Using a similar diffusion based mechanism, a Pd-nanoparticle 
functionalized electrode was used and changes in the ability of H2O2 to diffuse to the electrode 
surface was measured. When the miRNA was present, it effectively prohibited diffusion in a 
concentration dependent manner.  A detection limit of 1.7 pM can be achieved using this 
method.
107
 Additionally, these techniques show an extended dynamic ranging from 3-5 orders of 
magnitude. 
Labeling with electroactive tags 
Another approach to detect hybridization events is to label the miRNA:capture probe 
duplex with an electroactive species to yield a detectable signal. This was achieved by 
introducing copper ions to the hybrid which electrostatically interact with the negative nucleic 
acid backbone and catalyze the turnover of ascorbate.
108
 Similar approaches used methylene blue 
as a label.
109
 Methylene blue has a higher affinity for ssDNA versus miRNA hybrids. miRNA 
binding therefore decreased the electrochemical for methylene blue, as detected via voltammetry. 
The limits of detection for these approaches were reported as 8.2 fM and 0.5 fM, respectively. 
A further improvement is to directly label the miRNA:capture probe duplexes with either 
electroactive or catalytic labels. For example, aptamer based capture probes have been designed 
to bind HRP only when the miRNA is present. This approach offered picomolar LODs, but 
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suffered from the poor specificity of the aptamer sequence.
110
 Specificity was improved by using 
a miRNA:DNA specific antibody, S9.6, which, as illustrated in Figure 2.7A, could then be bound 
by an ALP-modified IgG antibody and used to achieve a LOD of 0.4 fM.
111
 Another approach 
involved ferrocene-boronic acid modified gold nanoparticles, where the boronic acid could form 
a covalent bond with the ribose sugar of the miRNA bound at the electrode surface. The 
electrochemical signal from the ferrocene group was then detected using differential pulse 
voltammetry to give a miRNA detection limit of 1 nM.
112
 
Sandwich hybridization based assays have also been shown to facilitate the addition of 
electroactive species, where a functionalized reporter DNA sequence hybridizes to a DNA 
capture probe only in the presence of the miRNA target. This approach had the benefit of 
facilitating the use of a wide variety of reporter tags and electroactive labels. Methylene blue 
(MB) labeled reporter sequences were designed to bind with the capture probe as well as 
additional helper sequences to allow the binding of 4 MB molecules per miRNA sequence. An 
LOD of 100 fM was reported using this assay, coined Sens
Q
, and multiplexing capabilities were 
demonstrated by the simultaneous quantitation of 3 miRNAs.
113
 The mechanism of this 
promising detection platform is shown in Figure 2.7B. 
Another approach utilized amino-functionalized reporter detection probes covalently 
bound to apoferritin-encapsulated copper nanoparticles. Hybridization of the target miRNA led 
to a pH shift at the electrode, resulting in the release of copper ions from the nanoparticles, 
which were detected with a LOD of 3.5 fM and a linear range spanning from 0.01 to 10 pM.
114
 
This assay was further modified using streptavidin functionalized reporter sequences to 
effectively bind multiple apoferritin nanoparticles per reporter strand due to the fact that 
streptavidin molecules can bind multiple biotins. Trypsase was used to digest the nanoparticles 
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and induce Cu release, and the multivalent streptavidin linkage improved the detection limit by a 
factor of 10—down to 0.35 fM, with a corresponding improvement in dynamic range.115  
Biotinylated reporter probes were also used to bind with ALP functionalized streptavidin 
to provide 0.4 pM LODs and a linear range from 1 pM to 100 nM.
116
 A similar approach using 
digoxin functionalized reporter sequences to bind with a HRP-functionalized anti-digoxin 
antibody claimed a LOD of 0.79 fM with a seven order of magnitude dynamic range. The key 
innovation of the digoxin based assay that leads to large improvement in sensitivity was the use 
of a Au and Ag modified dendrimer-chitosan-graphene composite electrode.
117
 The largest 
sensitivity enhancements were seen using biotinylated reporter sequences to bind with 
streptavidin functionalized titanium phosphate nanospheres that have incorporated Cd
2+
 ions. 
After binding of the nanospheres to the miRNA:capture probe duplex, [Ru(NH3)6]
3+
 
electrostatically interacted with the nucleic acid backbone and served as an electron carrier 
between the electrode surface and the nanosphere. The electrochemical response of Cd
2+
 was 
then used to quantify the presence of miRNA sequences. Impressively, this workflow reaches an 
LOD of 0.76 aM with linear range spanning seven orders.
118
 This impressive detection strategy is 
shown in Figure 2.7C. 
Redox cycling reactions have also been developed in an attempt to provide high 
sensitivity miRNA detection. These labeling approaches seek to eliminate diffusion limitations in 
solution using mercaptophenylboronic acid,
119
 APBA
120
 and DNAzyme
121
 functionalized gold 
nanoparticles. Despite promise, these early efforts did not show performance metric 
improvements over the previously discussed electroactive tagging approaches. 
Signal amplification via conjugation of multiple electroactive reporters 
49 
 
The small size of miRNA typically means that the sequence can only be covalently 
tagged with a single label. Similar to that described above for optical methods, target recycling 
methods can be employed to generate larger per-target electrochemical signals through either the 
hybridization chain reactions or enzymatic lengthening processing. Particularly effective 
strategies in this vein are highlighted in Figure 2.8. 
Enzyme free miRNA recycling techniques, such as mismatch catalytic hairpin assemblies 
that convert one miRNA molecule into a DNA duplex
122
 and toehold mediated strand 
displacement reactions
123
 have been interfaced with electrochemical detection to reach limits of 
detection of 0.6 pM and 1.4 fM, respectively. Sensitivities of the catalyzed hairpin assembly 
were improved 3-fold using TiO2 nanoparticles and redox cycling.
124
 Enzymatic recycling can 
also be achieved using double-stranded nuclease
125
 and T7 exonuclease,
126
 where LODs were 1 
fM and 0.17 fM, respectively. Significant improvements in sensitivity were when LNA G-
quaduplex-hemin DNAzymes were located in close proximity to the electrode surface. As the 
target miRNA target bound, it was degraded by double stranded nuclease making the DNAzyme 
more accessible to hemin binding and signal amplification. This gave an impressive detection 
limit of 8 aM; however, the linear range reported was prohibitively narrow.
127
 
Hybridization chain reactions are another amplification technique that do not require 
enzymatic processing yet can provide signal gain by improving accessibility for signal reporter 
molecules to intercalate between base pairs. Studies have used this workflow with [Ru(NH3)6]
3+
 
as an intercalating agent to achieve a six order of magnitude dynamic range and an LOD of 100 
aM.
128
 Li and co-workers were able to combine multiple p19 proteins on a magnetic bead and 
use a hybridization chain reaction mechanism using novel DSA molecules as signal reporters 
reporting a detection limit of 6 aM.
129
 Unfortunately, this assay is only linear over one order of 
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magnitude. Target recycling via RNaseA was also combined with the hybridization chain 
reaction using GC rich sequences that allow for enhanced DNAzyme activity resulting in a LOD 
of 100 fM with a dynamic range of over 5 orders of magnitude.
130
 
Other methodologies have combined DNA lengthening and target recycling amplification 
techniques. For example, catalyzed hairpin assembly and hybridization chain reaction were 
combined with a methylene blue-based read-out,
131
 and a nicking enzyme and DNA polymerase 
were utilized to amplify the miRNA target before a hybridization cascade using stem loop 
primers, which facilitated silver nanocluster association.
132
 Unfortunately, the limit of detection 
in both cases was higher than other electrochemical detection based systems, most likely due to 
the off target response of closely related miRNA species.
131
 Both assays reported dynamic ranges 
of 5 orders of magnitude. 
Additional enzymatic amplification approaches have also been investigated using a 
variety of DNA polymerase processing approaches. A simple approach used DNA polymerase to 
add biotinylated nucleotides as the miRNA strand was elongated to facilitate downstream 
streptavidin conjugated gold nanoparticle association and signal amplification. This provided a 
LOD of 99.2 fM and a dynamic range of four orders of magnitude. 
133
 An alternative approach 
used strand displacement amplification, enabled by a nicking enzyme and DNA polymerase, 
followed by sandwich hybridization of the capture probe, the amplification product, and then a 
biotinylated reporter sequence to bind to streptavidin-HRP conjugates. Using this approach an 
LOD of 40 pM is achieved with a dynamic range of 2 orders of magnitude.
134
 A third strategy 
relied on rolling circle amplification to lengthen a DNA sequence through the production of 
thousands of repeated sequences. This added sequence was used to conjugate redox probes
135
 or 
to prevent diffusion of electroactive species from the electrode surface,
136
 resulting in LODs of 
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100 fM and 1.2 fM and dynamic ranges of 4 and 2 order of magnitudes, respectively. Isothermal 
exponential amplification reaction (EXPAR) has also been explored via sandwich hybridization 
of the EXPAR product and a biotinylated reporter for ALP amplification
137
 or DNAzyme 
formation.
138
  
Lastly, an emerging method, shown in Figure 9A, used design rules from DNA 
nanotechnology to improve the orientation of capture probes at the surface, thereby mitigating 
the negative consequences of poor sterics of the electroactive labeling species and reducing and 
non-specific binding to the electrode surface. This general approach method was utilized in 
several different assay formats, including a sandwich hybridization assay,
139
 a target recycling 
process using a silver nanoparticle functionalized signal probe,
140
 a rolling circle amplification 
process,
141
 and with a hybridization chain reaction scheme.
142
 The LODs for these respective 
assays were 1 fM, 0.4 fM, 50 aM, and 10 aM respectively. Additionally, dynamic ranges 
spanned between 4-6 orders of magnitude. These results underscore how rational surface 
functionalization can have a profound effect on the ultimate performance of the sensor. 
Electrochemical impedance 
Electrochemical impedance is another electrochemical property that can be measured in a 
way to reflect the presence of a targeted miRNA sequence. Strategies to induce a change in 
charge transfer include the enzymatic turnover of an insulating polymer via DNAzymes,
143
 
hemin conjugated carboxylic graphene
144
 and DNAzyme functionalized gold nanoparticles.
145
 
These assays reported detection limits ranging from 100s of aM to 10 of fM LODs with dynamic 
ranges of 1.5, 3.5, and 4.5 orders, respectively. The assay that shows the largest gain to 
sensitivity and specificity of any label addition method is based on a three part impedance 
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system and developed by Labib and coworkers.
146
 Here, the first step of the assay was to 
measure the hybridization event of the target miRNA and RNA capture probe. If the signal could 
not be detected, the p19 RNA binding protein, which is specific to small 21-23 bp RNA duplex 
via electrostatic and hydrogen bonding interactions between the β-sheet formed by the p19 
homodimer and the sugar-phosphate backbone of the dsRNA, was used to amplify the 
impedance signal. Lastly, a DNA compliment could be added to induce the disassociation of the 
p19 protein from the electrode signal to further amplify the signal. All three steps form a “three-
mode” electrochemical sensor, and each “mode” had a different linear range that together 
allowed quantitative detection between 10 aM and 1 μM. This multi-step assay is highlighted in 
Figure 2.9B. Because of the non-specific nature of the p19 protein, multiplexing must be 
achieved by splitting the sample into separate volumes; however, the team reported a 3 plex 
assay in total RNA and validated the results with qPCR.   
Magnetic bead-enhanced electrochemical detection 
Mass transfer limits are significant hurdles to ultrasensitive target detection. An appealing 
general approach to circumvent these Langmurian limitations is to use magnetic beads that can 
diffuse quickly through solution to capture targets of interest, but then be localized onto the 
surface of a detection element using an external magnetic field. This approach has been widely 
exploited as a method of sample pre-concentration for a range of analyte classes in both label and 
label free measurement strategies. Below are several examples where magnetic beads were 
combined with electrochemical-based read out schemes. 
Using a similar inosine-substituted capture probe as described above, arrays of screen 
printed electrodes were used in combination with magnetic beads to enable multiplexed 
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measurement of miRNAs with increased sensitivity. After pre-concentration with magnetic 
beads, an alkaline treatment released the duplexes from the beads where they are then absorbed 
on graphite screen printed electrodes and guanine oxidation is measured. Multiplexing 
capabilities were shown by running three reactions in parallel with a limit of detection of 143 
nM.
147
  A different iteration of this workflow incubated miRNA solutions with Os(VI)bipy, 
which electrostatically associates to the miRNA. Magnetic beads with complimentary DNA 
capture probes were then used to capture target miRNA. The labeled target miRNA were 
thermally released and quantitated using the peak current detected from the Os label using a 
mercury drop electrode.
148
 The main drawback of this strategy this the limited dynamic range 
that covers approximately 1 order of magnitude. Additionally, redox cycling can improve 
specificity and extend dynamic range. Workflows have been presented that are dependent on the 
ligation of a magnetic bead functionalized capture probe and a biotinylated reporter sequence. 
Conjugation of SA-ALP to the complex catalyzes the production of an electroactive species, 1-
naphthol. The supernatant of this process is collected and introduced to a separate electrode, 
where the concentration of 1-napthol is measured through redox cycling. The LOD was reported 
to be 3.55 fM and a dynamic range of 4 orders of magnitude.
149
  
Magnetic moieties and electrodes have also been employed in tandem. For example, 
magnetic beads were used to detect biotinylated duplex specific nuclease products. In the 
presence of the target miRNA, the biotinylated probe was fully digested; however, in the absence 
of target, it was left intact. These products were absorbed onto a streptavidin coated magnetic 
bead and pulled down to a magnetic electrode, where an impedance measurement was made. The 
fully digested probes give lower impedance values compared to the intact capture probes that 
have a high charge density. This workflow resulted in an LOD of 60 aM and a dynamic range of 
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2 orders of magnitude.
150
 An alternative approach uses branching magnetic beads that hybridize 
to multiple miRNA targets through the formation of Y junctions. As a result of this branching, 
multiple HRP moieties could bind to the y junctions, and when pulled down to the electrode 
surface, could give a LOD of 0.22 aM and a four order of magnitude dynamic range.
151
 
An additional approach immobilizes the RNA duplex specific protein, p19, on magnetic 
beads and uses it as a capture probe for biotinylated RNA capture probe:miRNA hybrids 
following streptavidin-HRP conjugation. This complex was then pulled down to the electrode 
where a detectable catalytic current was measured giving a 40 pM LOD.
152
 However, the 
approximately 1 order of magnitude is limiting for many applications. The ultimate limit of this 
p19-based detection approach results from the nanomolar affinity of the RNA duplex:p19 
interaction, as a higher affinity would yield lower limits of detection. Lastly, a DNA ligase-
dependent sandwich hybridization/redox amplification strategy was reported having a gold 
nanocluster-ALP complex functionalized to a sequence-specific reporter. After ligation to the 
MB in the presence of the miRNA, the gold nanocluster-ALP complex catalyzed the production 
of silver nanoclusters which absorbed onto the bound DNA strand. The resulting product was 
then brought to the surface via a magnetic electrode and the silver content quantitated. The limit 
of detection using this approach is 21.5 aM with a dynamic range of 3 orders of magnitude.
153
 
2.3.3 Field Effect Transistors 
Field effect transistors (FETs) are an attractive class of sensors from the perspective of 
potentially low-cost devices that have high sensitivity to binding-induced changes in charge near 
the sensor surface. FETs have the added advantage of being easy to fabricate arrays of sensors, 
which enables facile multiplexing capabilities.  The sensing mechanism of FETs is illustrated in 
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Figure 2.9C. Recent efforts have aimed at demonstrating the versatility of this transducer through 
the use of CMOS-compatible silicon nanowire transistors,
154
 gold nanoparticle functionalized 
graphene FETs,
155
 and p19 functionalized FETs,
156
 with LODs of 0.13 fM, 10 fM, and 1 aM, 
respectively. The main drawback of this assay is the shallow sensing depth in solution, which is 
limited by the Debye length. This precludes the use of many labeling or strand extension 
techniques as they will occur outside the sensing window. 
2.4 Perspectives 
Since their discovery in the 1990s, our understanding of miRNAs has unraveled a new 
layer of regulatory control over gene expression in organisms. As the importance of miRNAs has 
become clearer, the number of platforms available to analyze these molecules has grown. 
Initially efforts focused on applying and modifying traditional techniques from molecular 
biology to allow for the analysis of miRNAs. For example, the creation of stem loop primers and 
new enzymatic methods that facilitated qRT-PCR and microarrays to be applied to this class of 
small RNAs. These techniques were essential to early breakthroughs; however, they are now 
being replaced with new workflows that offer greater coverage of global expression changes, as 
evidenced by the rapid gains in next generation sequencing. 
While RNA sequencing will continue to be a valuable tool for discovery and fundamental 
studies, emerging biosensor technologies are posed to play a role in translating basic 
biomolecular insights into the clinic. The last few years have seen tremendous growth in this 
area. Optical and electrochemical biosensors have been prominent for decades, but recent 
improvements in sensitivity, dynamic range, time to result, and surface functionalization have 
rendered them amenable to miRNA analysis. Novel materials and reagents, such as metallic 
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nanoparticles, semiconductor quantum dots, and intercalating small molecule fluorescent dyes, 
as well as advantageous electrical and optical properties of innovative micro- and nanostructures 
continue to open up new opportunities, resulting in detection limits down to aM levels and 
dynamic ranges spanning seven orders of magnitude. Additionally, these measurements have 
been made in a wide array of biofluids with minimal, if any, sample pre-treatment, greatly 
simplifying the analytical workflows compared to existing gold standard techniques from 
molecular biology. Armed with these and other new detection methodologies, the analytical 
community is now poised to shift attention from sensor development to deployment where the 
ultimate successes will be judged by the ability to make meaningful impacts in the clinical space. 
2.4.1 Future Improvements 
While emerging techniques have shown tremendous improvements in sensitivity, 
specificity, and dynamic range, advances are needed on several fronts in order for the ultimate 
potential of these technologies to be realized. More attention needs to be given to make these 
assays capable of making multiplexed measurements. Moreover, the development of disease-
relevant diagnostics will only be achieved through coupling with bioinformaticians to parse 
global expression profiles into clinically-actionable biomarker panels  
Challenges with multiplexing 
In recent years, it is becoming increasingly clear that miRNA panels can be used in 
clinical applications, as numerous reports describe the use of miRNA biomarkers for a range of 
human diseases.
157,158
 Additionally, systems level studies are revealing the interconnectivity 
between miRNAs and targets within regulatory networks. To this end, predictive bioinformatic 
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approaches are still needed to both predict miRNA targets and help deconvolve complex 
miRNA-mRNA regulatory interactions. 
Quite possibly due to a paucity of robust technologies able to perform multiplexed 
analysis on statistically-relevant patient populations, there are a limited number of reports that 
demonstrate the utility of multiplexed panels. As the push towards multiplexing continues, 
considerable challenges must be overcome in terms of differentiating between sequences having 
high levels of similarity, which is difficult to achieve because of subtle thermodynamic 
differences in hybridization-based assays. A further complication with multiplexing is dynamic 
range, as miRNAs expression levels can vary by more than 5 orders of magnitude, which would 
be difficult to span is sequences having highly disparate concentrations were included in a single 
panel. 
Optical detection methods have led the way in terms of the analytical capacity to perform 
multiplexed detection. Studies featuring both fluorescence and plasmonic sensors were used to 
demonstrate three-
52,55,61,70
 and four-plex
90,94
 assays with a relatively short time to result. 
However, increased clinical utility will likely be gained beyond proof-of-principle studies as the 
multiplexing is increased into the 10s of targets. Electrochemical sensors have also been shown 
to be promising for miRNA detection, with reported demonstrations of up to three-plex assays 
using a variety of different specific detection mechanisms.
113,146,147,151
 However, the 
instrumentation required to facilitate multiplexed detection requires either parallel analysis, 
which then requires multiple sample aliquots, or more complex instrumentation that involves 
multi-electrode configurations and multiple potentiostats. 
Challenges in informatics and the identification of disease-relevant miRNA panels 
58 
 
While the engineering of multiplexed detection approaches is promising from the 
perspective of technology alone, a significant challenge remains in the informatics behind panel 
construction. Next generations sequencing approaches can provide an almost overwhelming 
amount of expression information that must be informatically-reduced in the appropriate disease 
and population statistical context. As multiplexed detection approaches continue to mature, 
progress in informatics will ideally ripen at an equivalent rate. 
One difficulty in correlating miRNA expression with their functional effects on 
disrupting mRNA translation stems from how miRNAs are bioinformatically identified. As 
opposed to siRNA, miRNAs do not require a perfect antisense match against a potential mRNA 
target. These so-called “noncanonical” miRNA-mRNA interactions are not confined to 
translational repression through binding to the 3’ untranslated region (UTR) of the mRNA, as 
originally suspected, but play multiple complex and not completely understood roles in mRNA 
regulation.
159
 To this end, recent studies have aimed to build bioinformatics approaches that 
broadly consider both canonical and noncanonical miRNA-mRNA targets,
160,161
 and other 
promising computational tools applied to miRNAs have recently been reviewed.
162
 
In addition to challenges associated with target prediction, another layer of computational 
complexity lies in the fact that multiple miRNAs often act on single mRNA targets, and therefore 
it is difficult to conclude what effect a single miRNA has on a biological state. Despite this 
multi-factorial regulation, a number of single miRNA knockout studies exist in the literature 
although their relevance to a broad understanding of miRNAs in disease is not clear. Therefore, 
incredible opportunities exist for sensor scientists to work together with bioinformaticians to 
develop multiplexed panels that can together assemble technologies and relevant panels to help 
elucidate deep and meaningful correlations between multi-node regulatory networks. 
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Challenges in matching technologies to appropriate clinical needs 
In order to achieve widespread use outside academic labs, miRNA assays must be cost-
effective and easy to use. This is an important consideration when engineering signal 
amplification steps that require complicated liquid handling protocols. Additionally, researchers 
must consider the tradeoff between time to result and assay sensitivity. Depending on the 
application, label free assays that can be completed in 10 minutes might suffice; whereas, signal 
amplification techniques that provide sensitivity improvements that take 2 hours or more to 
complete might be required for other applications. Lastly, the pre-analytical requirements for 
different technologies and applications must be considered. That is, a label free assay might 
suffice for applications where miRNA has been extracted for a sample of interest, whereas one 
may have to leverage signal amplification and pre-concentration strategies to make high fidelity 
measurements directly from highly complex matrices. 
In order to optimize assays and determine the appropriate balance between time to result, 
sensitivity, and multiplexing capabilities, interdisciplinary collaborations between analytical 
chemists, clinical chemists, clinical practitioners, and statisticians/bioinformaticians will be 
essential. Appropriate large sample set studies will not only validate emerging sensor 
technologies, but more importantly also establish the broad utility of panel-based diagnostics that 
will then have impact beyond any one specific technology platform.  
2.4.2 Brief Conclusions 
Though many of the challenges outlined above are significant, the miRNA sensing field 
is poised for a bright future. Keeping in mind the great strides that have been made to overall 
60 
 
assay attributes (i.e. sensitivity and dynamic range), miRNA detection using emerging 
biosensing technologies is far beyond the proof-of-principle stage. The next few years will 
hopefully show a shift away from fundamental sensor development towards the identification 
and validation of multiplexed panels, and then onto clinical translation. Strategic collaborations 
should enhance this process as bioinformatic approaches evolve alongside detection technology 
maturation. These collaborations will help catalyze this shift in focus from further pushing LODs 
and performing proof-of-concept sensing studies to placing instrumentation in clinical settings to 
revolutionize diagnostic capabilities by supporting or replacing current gold standard techniques. 
Although there are sure to be challenges along the way, the ultimate goal of sensitive, 
multiplexed, and easy to use miRNA detection devices is on the horizon, and will hopefully help 
miRNAs fill a key role in the realization of informative diagnostics guiding individualized 
medicine. 
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2.5 FIGURES AND TABLES 
 
 
Figure 2.1: Growth in publications in microRNA profiling since 2006. These results were 
obtained from a SciFinder search using the key words “microRNA detection”. 
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Figure 2.2: Biogenesis of miRNA that starts with transcription in the nucleus and ends with 
affecting gene translation in the cytoplasm. 
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Figure 2.3: Overview of conventional techniques: (a) qRT-PCR, (b) microarrays and (c) next 
generation RNA sequencing. (A) When using TaqMan qRT-PCR, the reverse transcription 
process utilizes stem-loop primers specific to the miRNA target of interest.  During PCR 
amplification, the DNA polymerase proceeds along the template strands produces by miRNA 
specific forward and reverse primers and hydrolyses the TaqMan probe bound to the template.  
This liberates the fluorescent dye from the quencher and results in light emission.  In SYBR 
green-based approaches, miRNAs are typically polyadenylated at the 3’ end and d(T) oligos are 
used as the reverse transcription primer.  PCR amplification is carried out using miRNA specific 
forward primer and reverse primer.  SYBR Green, an intercalating dsDNA dye, is then used to 
monitor PCR product formation. (B) DNA-based capture probes immobilized on the microarray 
are used to capture fluorescently tagged miRNAs.  The fluorescent signal is then quantitated and 
the intensity is related to the relative miRNA expression. (C) Most RNA-sequencing workflows 
begin by reverse transcribing miRNA into a cDNA library.  This is followed by adaptor ligation 
that allows for immobilization on a substrate that are used to obtain sequencing data. 
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 qRT-PCR Microarrays Next Gen. Sequencing 
Time to result Hours Days Weeks 
Cost $$ $ $$$ 
Biochemical 
processing 
Ligation with T4 (SYBR 
Green) 
Annealing of primers 
No ligation steps Ligate barcode 
Input Low (ng) Large (ng-μg) Large (ng-μg) 
Drawbacks 
Results need validation 
Long time to result 
Single plex 
Don’t always need 
global view 
Table 2.1: Comparison of conventional miRNA detection platforms 
 
 
 
 
 
 
 
 
 
65 
 
 
Figure 2.4: Promising multiplexed detection schemes. (A) Fluorescent FRET pairs were used to 
probe miRNAs-141, 21, and 126 in multiple cancer cell lines.  Reproduced from Wu, P.; Tu, Y.; 
Qian, Y.; Zhang, H.; Cai, C. Chemical Communications 2014, 50, 1012-1014 (ref 52), with 
permission of The Royal Society of Chemistry.  (B) Quantum dot FRET pairs were also used to 
profile three miRNAs from diluted serum.  Reproduced from Qiu, X.; Hildebrandt, N. ACS 
Nano 2015, 9, 8449-8457 (ref 55).  Copyright 2015 American Chemical Society.  (C) FRET-
based detection was achieved using a fluorescent peptide nucleic acid detection probe adsorbed 
onto a graphene oxide nanosheet as a quencher.  miRNA-21, 125b, and 96 were quantitated in 
living cells and the relative expression levels were shown to correlate well with Northern 
blotting.  Reproduced from Ryoo, S.-R.; Lee, J.; Yeo, J.; Na, H.-K.; Kim, Y.-K.; Jang, H.; Lee, J. 
H.; Han, S. W.; Lee, Y.; Kim, V. N.; Min, D.-H. ACS Nano 2013, 7, 5882-5891 (ref 61).  
Copyright 2013 American Chemical Society. 
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Figure 2.5: Target recycling approaches. (A) Duplex specific nuclease recycling was used to 
study the differential expression of three miRNAs in six cancer cell lines.  Reproduced from Yin, 
B.-C.; Liu, Y.-Q.; Ye, B.-C. Journal of the American Chemical Society 2012, 134, 5064-5067 
(ref 70).  Copyright 2012 American Chemical Society.  (B) Toehold-mediated amplification 
facilitated effective target recycling and detection of miRNA-21 in four cell lines.  However, 
improvements to this assay could focus on quantitating multiple targets per sample.  Reprinted 
from Analytica Chemica Acta, Vol. 888, Huang, R.; Liao, Y.; Zhou, X.; Xing, D. Toehold-
mediated nonenzymatic amplification circuit on graphene oxide fluorescence switching platform 
for sensitive and homogeneous microRNA detection, pp. 162-172 (ref 71).  Copyright 2015, with 
permission from Elsevier.  (C) A nickase based recycling strategy combined with the use of a 
DNA polymerase exponentially amplified nucleic acid sequences related to the target of interest.  
These dsDNA produces were stained with an intercalating fluorescent dye, and the signal 
intensity was proportional to the initialtarget concentration.  Reproduced from Liu, H.; Li, L.; 
Wang, Q.; Duan, L.; Tang, B. Analytical Chemistry 2014, 86, 5487-5493 (ref 73).  Copyright 
2014 American Chemical Society. 
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Figure 2.6: Successful multiplexing strategies using plasmonic based biosensors.  (A) Plasmonic 
nanowires detected the presence of four miRNA targets using locked nucleic acid capture probes 
and Cy5 functionalized reporter locked nucleic acid sequences.  These optimized nanosensors 
were used to profile the expression of four miRNAs from RNA isolated from two tissue types.  
Reproduced from Ultra-Specific Zeptmole microRNA Detection by Plasmonic Nanowire 
Interstice Sensor with Bi-Temperature Hybridization, Kang, T.; Kim, H.; Lee, J. M.; Lee, H.; 
Choi, Y.-S.; Kang, G.; Seo, M.-K.; Chung, B. H.; Jung, Y.; Kim, B. Small, Vol. 10, Issue 20 (ref 
91).  Copyright 2014 Wiley.  (B) A novel ultra-low fouling surface plasmon resonance imaging 
biosensor detected four miRNAs from erythrocyte lysate.  A gold nanoparticle signal 
enhancement strategy was used to improve limits of detection.  Clinical utility was shown by 
analyzing chances in expression profiles of miR-16, 181, 34a, and 125b in ‘normal’ clinical 
samples and ones with myelodysplastic syndrome. Reprinted from Biosensors and 
Bioelectronics, Vol. 70, Vaisocherová, H.; Šípová, H.; Víšová, I.; Bocková, M.; Špringer, T.; 
Laura Ermini, M.; Song, X.; Krejčík, Z.; Chrastinová, L.; Pastva, O.; Pimková, K.; Dostálová 
Merkerová, M.; Dyr, J. E.; Homola, J., Rapid and sensitive detection of multiple microRNAs in 
cell lysate by low-fouling surface plasmon resonance biosensor, pp. 226-231 (ref 95).  Copyright 
2015, with permission from Elsevier.  
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Figure 2.7: Promising electrochemical signal enhancement approaches by adding an 
electroactive label to miRNA:DNA hybrids. (A) Labeling was achieved using the S9.6 antibody 
that binds specifically to RNA:DNA heteroduplexes.  After antibody binding, ALP was then 
conjugated to the surface and provided an electrochemical signal.  Reprinted from 
Electrochemica Acta, Vol. 165, Wang, M.; Li, B.; Zhou, Q.; Yin, H.; Zhou, Y.; Ai, S. Label-free, 
Ultrasensitive and Electrochemical Immunosensing Platform for microRNA Detection Using 
Anti-DNA:RNA Hybrid Antibody and Enzymatic Signal Amplification, pp. 130-135 (ref 111).  
Copyright 2015, with permission from Elsevier.  (B) Nanoparticle labeling was achieved using 
biotin-streptavidin attachement chemistry.  This approach was used to identify changes in 
miRNA-21 expression in serum between healthy patients and patients with various cancer types.  
Reproduced from Cheng, F.-F.; He, T.-T.; Miao, H.-T.; Shi, J.-J.; Jiang, L.-P.; Zhu, J.-J. ACS 
Applied Materials & Interfaces 2015, 7, 2979-2985 (ref 118).  Copyright 2015 American 
Chemical Society. (C)  A sandwich hybridization based labeling approach was developed using 
methylene blue conjugated reporter probes that bound to the surface only when the miRNA was 
present.  This strategy effectively placed four methylene blue molecules near the electrode for 
every one target miRNA, allowing for effective signal amplification.  The power of this strategy 
was sown by detecting three miRNAs in parallel.  Reproduced from Labib, M.; Khan, N.; 
Berezovski, M. V. Analytical Chemistry 2015, 87, 1395-1403 (ref 113).  Copyright 2015 
American Chemical Society.   
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Figure 2.8: Electrochemical signal amplification using enzymatic approaches to modify the 
miRNA:capture probe structure at the sensor surface. (A) Target recycling via RNase A was 
initially used to increase the number of targets that bound to the surface.  The detectable 
electrochemical signal was then amplified via hybridization chain reaction which formed 
multiple hemin associated G-quadruplexes and thus an electrochemical signal.  Reprinted from 
Sensors and Actuators B, Vol. 195, Xiang, G.; Jiang, D.; Luo, F.; Liu, F.; Liu, L.; Pu, X. 
Sensitive detection of microRNAs using hemin/G-quadruplex concatamers as trace labels and 
RNA endonuclease-aided target recycling for amplification, pp. 515-519 (ref 130).  Copyright 
2014, with psermission from Elsevier.  (B)  A nicking enzyme based recycling strategy that 
relies on DNA polymerase amplification was used to create multiple detection sequences that are 
proportional to the miRNA target concentration.  This is followed by hybridization chain 
reaction where the primers are designed to associate with silver nanoclusters.  Reproduced from 
Yang, C.; Shi, K.; Dou, B.; Xiang, Y.; Chai, Y.; Yuan, R. ACS Applied Materials & Interfaces 
2015, 7, 1188-1193 (ref 132).  Copyright 2015 American Chemical Society.  (C) Rolling circle 
amplification was also shown to be an effective way to facilitate binding of multiple 
electroactive species, in this case Ruhex, per miRNA target.  Reproduced from Yao, B.; Liu, Y.; 
Tabata, M.; Zhu, H.; Miyahara, Y. Chemical Communications 2014, 50, 9704-9706 (ref 135), 
with permission of The Royal Society of Chemistry.  
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Figure 2.9: General electrochemical sensing improvements and additional strategies for 
generating a detectable signal. (A) DNA nanotechnology has been used to improve surface 
functionalization by ensuring reproducible capture probe orientation at the electrode surface.  
Reproduced from Ge, Z.; Lin, M.; Wang, P.; Pei, H.; Yan, J.; Shi, J.; Huang, Q.; He, D.; Fan, C.; 
Zuo, X. Analytical Chemistry 2014, 86, 2124-2130 (ref 142).  Copyright 2014 American 
Chemical Society.  (B) Impedance can be used to detect the presence of miRNAs.  Here, three 
different detection regimes (label free detection, protein binding based signal amplification, and 
protein dissociation based signal amplification) were identified to extend the dynamic range over 
10 orders of magnitude.  Reproduced from Labib, M.; Khan, N.; Ghobadloo, S. M.; Cheng, J.; 
Pezacki, J. P.; Berezovski, M. V. Journal of the American Chemical Society 2013, 135, 3027-
3038 (ref 146). Copyright 2013 American Chemical Society.  (C) Based on impedance, field 
effect transistors are a simple way to achieve multiplexing capabilities with very low limits of 
detection.  Reproduced from CMOS-Compatible Silicon Nanowire Field-Effect Transistors for 
Ultrasensitive and Label-Free microRNAs sensing, Lu, N.; Gao, A.; Dai, P.; Song, S.; Fan, C.; 
Wang, Y.; Li, T. Small, Vol. 10, Issue 10, (ref 154).  Copyright 2014, Wiley.  
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3.1 Introduction 
MicroRNAs (miRNAs) constitute an important class of non-coding RNAs that regulate 
gene expression at the transcriptional and post-transcriptional level. As potent gene regulators, 
miRNAs have been linked to important developmental processes that establish and maintain 
tissue differentiation.1,2 Not surprisingly, miRNA expression in tissue and blood samples is 
associated with disease and has substantial diagnostic utility.3,4 However, the short sequence 
lengths, large variability in per-cell copy number, and high sequence similarity within families of 
expressed miRNAs conspire to make them challenging analytical targets. Furthermore, miRNAs 
often function in complex regulatory networks whereby many miRNAs work cooperatively to 
regulate the expression of a single mRNA transcript. However, each miRNA may be involved in 
many different transcript-targeting regulatory networks. Therefore, the multiplexed detection of 
many miRNAs simultaneously is an important consideration for both fundamental and 
translational application of miRNA analysis technologies. For clinical applications, these 
complications are further exacerbated by technical and practical requirements, including small 
sample sizes, low cost, and relative ease of use. Therefore, candidate miRNA detection 
technologies need to offer: high sensitivity; wide dynamic range; high sequence specificity; 
multiplexing capability; and minimal sample processing and handling.5 
 Current miRNA detection techniques are lacking in one, or more, of these attributes. 
Specifically, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) methods 
are incredibly sensitive, relatively rapid, and cost effective; however, they typically measure 
levels of only a single miRNA sequence per assay. Conversely, microarrays are well-suited to 
multiplexed analyses but are typically slow, less sensitive, more expensive, and require PCR 
amplification, which can introduce sequence biases. Next-generation sequencing technologies 
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give a comprehensive picture of miRNA expression levels; however, this global approach, which 
requires complex library construction and onerous informatics, is both time- and cost-prohibitive 
for many diagnostic applications. Moreover, advances in database informatics have found that 
reduced subsets of miRNAs can be identified that offer robust and actionable diagnostic utility.6 
Therefore, technologies that can robustly determine expression levels of targeted panels of 
miRNAs from a single, clinically-relevant sample could be important in the widespread 
realization of translational miRNA-based diagnostics. 
Silicon photonic microring resonators, which belong to a larger class of whispering 
gallery biosensors,7 are an intrinsically multiplexable, array-based technology that has been 
applied to a range of biomolecular detection applications.8-13 The operational theory and 
measurement instrumentation behind the technology has been previously discussed in detail.14-15 
Briefly, a tunable wavelength laser centered around 1550 nm is coupled into linear waveguides 
via on chip grating couplers. The laser is swept through the appropriate spectral window to 
determine wavelengths of optical resonance. Changes in the local refractive index near the sensor 
surface induced by biomolecular binding cause a shift in the resonance, with shifts directly 
proportional to the amount of surface bound biomolecules, which in turn reflects the solution 
phase analyte concentration. A more detailed description of this technology is presented in the 
Supporting Information.  
Our group previously demonstrated the detection of miRNAs using microring resonators 
in both a label-free
16
 and capture-agent-enhanced
17
 assay format, the latter using a DNA:RNA 
heteroduplex-specific antibody. Here we report a sandwich-based detection protocol that uses 
reverse transcription to create cDNA products of targeted miRNAs that are subsequently 
detected using an enzymatic chemical signal enhancement strategy. Compared to prior work 
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from our group,
17
 we report improved limits of detection, increased levels of multiplexing, but 
most dramatically, an ~85% reduction in analysis time (from 12-15 hours to 2.5 hours).  To our 
knowledge, this is the first report that directly detects cDNA products resulting from miRNA 
reverse transcription using specific stem loop primers (SLP), rather than being integrated with 
the standard RT-qPCR framework, which has intrinsic limits in terms of multiplexing capacity. 
We demonstrate the broad applicability of this approach by profiling the expression levels of 7 
miRNAs, and an off target control sequence, to differentiate between different tissue types, 
showing good correlation with previous RT-qPCR analyses.  
3.2 Experimental Details 
3.2.1 Materials 
UltraPure DEPC-treated water (Life Technologies) was used for all experiments. A 10X 
PBS buffer (pH 7.4) was diluted to 1X and used to reconstitute all nucleic acid samples. A high 
stringency hybridization buffer consisting of 30% formamide, 0.2% sodium dodecyl sulfate, 4× 
saline−sodium phosphate−ethylenediaminetetraacetic acid (EDTA) buffer (SSPE, USB Corp.), 
and 3× Denhardt’s solution (Invitrogen) was used for all nucleic acid hybridization steps. A PBS 
running buffer (pH 7.4) was reconstituted with 0.05% Tween20 and was used to dilute all protein 
containing steps. The silane (3-aminopropyl)triethoxysilane (APTES) was purchased from 
Fisher. All custom synthesized nucleic acid sequences were obtained from Integrated DNA 
Technologies (IDT; Coralville, Iowa). Nucleic acid sequences are included in Table 3.1. miRNA 
RT-PCR kits used for RT-qPCR profiling were purchased from Life Technologies, and target 
specific assay IDs are listed in Table 3.2. Drycoat Assay Stabilizer solution was purchased from 
Virusys Corporation and used as received. Streptavidin-conjugated horseradish peroxidase (SA-
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HRP), one-step 4-chloro-1-napthol solution, and all other reagents were purchased from 
ThermoFisher and used as received. 
3.2.2 Instrumentation  
Sensor chips and read-out instrumentation were obtained from Genalyte, Inc. (San Diego, 
CA). Sensor chips were fabricated at a silicon foundry on 8 in. silicon-on-insulator wafers using 
deep UV photolithography and dry etch methods, spin-coated with a fluoropolymer cladding 
layer, and diced into individual 4 × 6 mm chips, each having an array of 132 individually 
addressable microrings. The fluoropolymer cladding is selectively removed from 128 of the 
rings, leaving these exposed to the solution and responsive to binding events. The four occluded 
rings serve as control elements for subtracting thermal drift. Chips were fitted with a laser etched 
Mylar gasket, which defines flow chambers when sandwiched with a Teflon lid, and loaded into 
the readout instrumentation. All experiments were performed with automated fluidic handling 
using the recipes summarized in Table 3.3. 
Resonant wavelengths for each microring were determined by coupling a tunable laser 
source (centered at 1560 nm) into an adjacent linear waveguide via on-chip grating couplers. The 
laser output was then swept through an appropriate spectral window and the light intensity at the 
distal end of the linear waveguide was used to determine the resonance wavelength. This process 
was then serially repeated for each ring in the array, and the resultant shifts in resonance as a 
function of time were recorded. 
The resonance condition that is supported by the microring resonators is governed by the 
following equation: 
mλ = 2πrn
eff
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where m equals a nonzero integer, λ is the wavelength of propagating light, r is the microring 
radius, and neff is the effective refractive index of the local microring environment. Boundary 
conditions of light propagating in linear waveguides via total internal reflectance result in an 
evanescent field extending into a region very close to the ring surface. Interactions between the 
evanescent field and the local environment cause a change in the resonant wavelength, which is 
then monitored by the optical scanning instrumentation. Therefore, the binding of higher 
refractive index biomolecules and accompanying displacement of water results in a resonance 
shift to longer wavelengths: a positive shift that is listed in units of Δ picometers (Δpm). 
3.2.3 Sensor Surface Functionalization with Capture Probes 
Prior to covalent modification of capture probes, sensor chips were cleaned in a piranha 
solution (3:1 H2SO4/30% H2O2) for 35 seconds.  (Caution: Piranha solutions are extremely 
dangerous and react explosively with organics.)  Following a 2 min rinse in acetone, chips were 
incubated in APTES (5% in acetone) for 4 minutes.  After rinsing sensor chips in acetone (2 min) 
followed by IPA (2 min), a bis(sulfosuccinimidyl)suberate solution (25 μL, 2.85 mg/mL in acetic 
acid), an amino-to-amine crosslinker, was pipetted onto the sensor surface and left to incubate 
for 3 minutes. Chips were dried with N2, and then small aliquots (300 nL) of an aminated DNA 
capture probe specific to an individual miRNA target were deposited onto the microring surface 
so that the solution covers a specific set of microrings.  The chips were left in a humidity 
chamber (1 hour).  Then, they were rinsed in Drycoat Assay Stabilizer solution and stored at 4°C 
until use. 
3.2.4 Preparation and Addition of miRNA Target to Sensor Surface 
Target miRNA solutions were first reverse transcribed according to the manufacturer’s 
protocol (TaqMan microRNA Reverse Transcription Kit, Life Technologies) using the following 
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thermal profile:  16°C (30 min), 42°C for (30 min), and 85°C (5 min). Following reverse 
transcription, the solution was incubated in equal volume alkaline hydrolysis buffer (50 mM 
Na2CO3, 1 mM EDTA, pH 8.5) at 95°C for 30 min.  An aliquot of this solution was then diluted 
100 fold in hybridization buffer (4 μL sample aliquot in 396 μL hyb) and to that a biotinylated 
DNA probe (0.4 μL, 200 μM) that is complimentary to the “stem” region of the stem loop primer 
is added. This solution is incubated at 72°C for 10 min. After incubation, the solution is allowed 
to cool back to room temperature and loaded into a 96 well plate for subsequent analysis on chip. 
For on chip analysis, the diluted miRNA target sequences were flowed at 15 μL/min for 
14 min. For total RNA analysis, the solution was allowed to hybridize for 25 minutes. A sensor 
baseline was established before and after hybridization by flowing hybridization buffer (30 
μL/min) for 3 min and 1 min respectively. 
3.2.5 Horseradish Peroxidase Enzymatic Amplification 
Following miRNA hybridization, a PBST (0.05% Tween20) solution is flowed across the 
surface (30 μL/min) for 5 minutes to establish a new baseline resulting from the running buffer 
change.  Afterwards, a solution of SA-HRP (4 μg/mL) is introduced (30 μL/min, 3 min) and 
binds to the biotinylated compliment that is bound on the sensor surface. This is followed by 
another PBST rinse (30 μL/min, 2 min) to prepare the surface for 4-CN precipitation. 4-CN is 
then introduced to the sensor (30 μL/min) for 9 min, and a final buffer rinse (30 μL/min) is 
conducted for 3 min to establish the net sensor response before and after 4-CN amplification.  It 
is important to note that the surface can be regenerated on the microring sensor chips without a 
decrease in performance. 
*Complete outline of automated fluidic handling shown in Table 3.3. 
 
91 
 
3.2.6 Total RNA Samples 
Both brain (Lot No. 1307018) and lung (Lot No. 1410019) total RNA samples isolated 
from patient tissue were obtained commercially (Life Technologies) and stored at -80°C until 
further use.  Samples were thawed on ice for approximately 2 hours prior to use, and a 1 μg and 
100 ng input amount was used for microring and RT-qPCR analysis respectively.   
3.2.7 Data Analysis 
Data analysis was performed using Origin Pro 9.0.  All data was corrected for 
temperature drift, bulk refractive index shifts and differential sensor response by subtracting the 
response of control rings functionalized with a non-complementary capture probe from the active 
rings.  To calculate the initial slope of DNA binding, we used a modified 1:1 Langmuir Binding 
Isotherm, as described by: 
 
𝑆(𝑡) = 𝐴(1 − 𝑒−𝐵(𝑡−𝑡0)) 
 
To determine the initial slope of the binding response, the first derivative of the previous 
equation was evaluated at t = t0, yielding: 
𝑑𝑆
𝑑𝑡
= 𝐴𝐵 
 
The average of the initial slopes was taken over a number of sensors for each concentration.  As 
a general rule, the first 5 minutes of collected data was used to obtain the fit.  For low 
concentrations where the modified Langmuir Binding Isotherm could not effectively fit the 
sensor trace, a linear fit was used to approximate the initial slope. 
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3.2.8 RT-qPCR 
For RT-PCR experiments, total RNA (100 ng) was used. Reverse transcription was 
performed using TaqMan microRNA Reverse Transcription Kit (Life Technologies) and 
miRNA-specific stem loop primers provided in the kit (see Table S2 for miRNA specific Assay 
IDs). Reverse Transcription was carried out on a BioRad T100 Thermal cycler at 16°C (30 min), 
42°C for (30 min), and 85°C (5 min).  RT products were then subjected to quantitative PCR in 
triplicate using PCR primers from the same miRNA Assay Kit.  The reaction was performed at 
95°C (10 min), followed by 40 two-step cycles of (1) 95°C for 15 s and (2) 60°C for 1 min.  All 
quantitative PCR work was done using an Applied Biosystems 7900HT Fast Real-Time PCR 
System. All procedures and reactions were carried out according to the protocols provided by the 
manufacturer. Levels of miRNAs were normalized to miR-26a, and fold change was calculated 
using the 2^(-ΔΔCt) method. 
3.3 Results and Discussion 
A schematic of the reverse transcription-horseradish peroxidase (RT-HRP) assay is 
shown in Figure 3.1. SLPs are designed with a universal stem loop sequence and a 7-8 nucleotide 
overhang sequence specific for particular miRNA targets. Hybridization of the miRNA target to 
the SLP followed by extension via reverse transcription yields the DNA complement to the 
miRNA sequence. The miRNA is then degraded via base hydrolysis (Figure 3.2) leaving the RT 
product accessible to bind to the capture probe attached to the sensor surface. Without 
degradation, the hybridized miRNA can block the capture probe recognition site on the RT 
product (Figure 3.3). 
After extension and RNA degradation (RT SLP), a biotinylated tag sequence of DNA 
complementary to the conserved stem loop region common to all of SLPs was added to the 
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solution containing RT products. This solution is incubated at 72°C, which allows for the stem 
loop sequence to linearize and hybridize to the tag. SLPs were designed with a one base pair 
mismatch in the stem region so that tag-RT SLP complexes are thermodynamically preferred 
over the secondary structure of the SLPs themselves (Tm of tag-RT SLP > Tm SLP secondary 
structure). In this way, the complex remains linear and able to hybridize to surface-bound capture 
probes on the microring sensors, leading to a 20-fold increase in sensitivity when compared to 
results obtained using conventional stem loop primers with the RT-HRP assay (Figure 3.3). 
Importantly, this strategy is capable of targeting multiple miRNAs in a single sample volume by 
adding multiple SLP sequences to the initial RT reaction and presents a streamlined sample 
preparation process that consists of only 3 incubation steps over the course of ~1.75 hours. 
The HRP-enhanced sensing strategy of the target sequences is shown in Figure 3.1B. 
While we have previously utilized HRP signal amplification for protein detection,11 this is the 
first report to use HRP for the detection of miRNAs. The solution containing tag-RT SLPs is 
diluted in a high stringency hybridization buffer to ensure complementary binding and then 
flowed across an array of microring sensors uniquely-functionalized with target-specific DNA 
capture sequences. Additionally, capture probes were designed to avoid hybridization with non-
extended SLPs. After hybridization of tag-RT SLPs to the ssDNA capture probes and a 
streptavidin-HRP conjugate was flowed across the sensor surface. A solution of 4-chloro-1-
napthol (4-CN) was then introduced and enzymatically converted into insoluble 4-chloro-1-
napthon (4-CNP) by bound HRP. The deposition of the 4-CNP precipitate causes a dramatic shift 
in the resonance wavelengths of the microrings (measured in picometers; pm) that is directly 
related to the number of surface bound HRP moieties and thus the concentration of target 
miRNAs in the original sample matrix.  
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To demonstrate the quantitative ability of the developed scheme, we exposed the 
microring sensors functionalized with a target specific capture probe to 7 cDNA product 
solutions of the miRNA target ranging in initial concentrations from 2 μM to 2 nM, as well as a 
blank (no input RNA). Calibration curves were generated by diluting synthetic miRNA 
sequences to the different concentrations, subjecting these solutions to the RT-HRP protocol, and 
quantitating the initial slope of the HRP amplification response. Figure 3.4A shows 
representative binding curves that were used to compile the calibration curves in Figure 3.4B. 
Clear concentration-dependent responses were seen across a 4 order of magnitude dynamic 
range, as shown in Figure 3.4B, which also lists the determined limits of detection for each target 
sequence. 
Next, we show the applicability of this approach for multiplexed measurements of seven 
different miRNA targets. Notably, the use of the conserved region on the biotinylated stem loop 
primers as a universal recognition element reduces assay complexity by eliminating the need for 
multiple tagging sequences. Microring resonators were spatially arrayed via functionalization 
with eight unique capture probes (7 specific to miRNA targets and one negative control). Seven 
chips were identically functionalized and each exposed to solutions containing the RT-product of 
individual miRNAs at a constant input of 10 picomoles. This process was repeated for each of 
the seven miRNA targets, and the compiled results are shown in Figure 3.5. Each column in the 
figure represents a different sensor array incubated with the RT product of the target on the 
column heading. As can be seen, this detection approach had high sequence specificity for the 
targeted miRNAs and minimal cross-reactive response. 
To demonstrate that this approach is able to probe more complex samples, and also to 
benchmark the assay against gold standard techniques (i.e. RT-qPCR), we simultaneously 
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profiled the expression of seven miRNAs from brain and lung total RNA samples (Figure 3.6). 
The detected concentrations are shown in Figure 3.7A. Likewise, we used RT-qPCR to compile 
expression profiles from the same sample (see Table 3.4 for C(t) values). After normalizing both 
data sets by dividing by the concentration measured for miR-26a, which corrects for sampling 
differences,17 the fold change of brain:lung miRNA expression was determined and plotted in 
Figure 3.7B, together with ratios calculated based upon a previous study.18 
The relatively large fold-change deviations for miR-219 might be explained by the fact 
that the low overall expression levels cause the analysis to approach the C(t) cutoff threshold for 
reliable detection using RT-qPCR, and also increase the microring measurements susceptibility 
to any analytical errors. That said, both platforms are in agreement with the literature that 
miRNA-219 is more abundant in brain tissue.19 Similarly, the detection of miR-21 could also be 
unreliable since it is an oncogene that is upregulated during cancer progression,20 whereas the 
samples analyzed were not from cancer patients. Interestingly though, if the expression is 
assumed to be one order of magnitude lower than our limit of detection, the brain:lung fold 
change correlates well with literature precedent,18 as well as our in-house RT-qPCR 
measurements. 
3.4 Conclusions 
In conclusion, we have developed a new approach for the sensitive and multiplexed 
analysis of miRNAs using a reverse-transcription-enabled enzymatic signal enhancement 
strategy coupled with detection using silicon photonic microring resonators. While only shown 
for seven targets here, this technology is capable of delivering significantly higher levels of 
multiplexing, which exceed that of many other emerging miRNA detection strategies.5  
Moreover, this type of platform offers the capacity to analyze for panels of miRNAs not easily 
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accessible via RT-qPCR while avoiding the cost and informatics required for RNA sequencing, 
and therefore may be well-positioned to fit an important niche in helping translate miRNA-based 
diagnostics to the clinic. Future efforts to further improve the analytical performance metrics of 
the methods will be required in addition to more clinically- relevant demonstrations more 
closely-targeted to specific disease diagnoses and from expanded patient cohorts. 
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3.5 FIGURES AND TABLES 
 
Figure 3.1: A) Schematic diagram of miRNA processing to prepare for on chip detection. B) 
Illustration of RT product detection and HRP signal amplification. C) The representative binding 
curve shows data corresponding to the detection of a 10 picomole miRNA-26a sample subjected 
to the workflow in A and B. The large signal gain at 30 minutes is obtained from the 4-chloro-1-
napthon deposition. 
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Figure 3.2:  Agarose gel analysis hydrolysis buffer efficiency. Three samples were analyzed 
on an ethidium bromide stained 2% agarose gel (0.5x TBE running buffer) to assess the 
efficiency of the alkaline hydrolysis buffer. Lanes A and B show samples that have been reverse 
transcribed (30 picomole input of miR-26a) and incubated with either alkaline hydrolysis buffer 
(lane A) or water (lane B). This result confirms that the alkaline hydrolysis buffer successfully 
hydrolyzes the RNA. The band intensity analysis (ImageJ) shows that the hydrolyzed sample is 
approximately 50% less intense than the control group. 
A       B       C 
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Figure 3.3: Effect of alkaline hydrolysis buffer and stem loop primer construction on 
sensor response. A 10 picomole input of miRNA-26a was used and subjected to the RT-HRP 
assay under three different conditions. The response for experiments that had a perfectly 
complimentary SLP (Tm = 79.6°C) showed no binding response as the probe was not linearized 
and able to bind to the sensor surface. Responses were observed when a single nucleotide 
mismatch was introduced into the SLP design (Tm = 61.8°C); however, the signal was 
dramatically increased when the miRNA was degraded using hydrolysis buffer. These results 
show that the stem loop primer choice and miRNA degradation via alkaline hydrolysis are 
essential steps in the assay design. 
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Figure 3.4: A) Overlay of the signal responses achieved for each concentration dilution of target 
miRNA cDNA product. Initial concentrations utilized were: 2 μM (black), 1 μM (red), 200 nM 
(blue), 20 nM (pink), 2 nM (green), and a blank (purple). B) Calibration curves for the HRP 
response of each miRNA target. The red curves represent linear fits of the initial slope of the 
HRP amplification step. Error bars represent the standard deviation of between 8 and 20 
technical replicates at each concentration. 
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Figure 3.5: Detection of specific miRNA target products with minimal off target response from 
non-complementary capture probes. Each column represents a sensor chip arrayed with different 
capture probes and exposed to the miRNA RT product listed as the column heading. Each row 
represents the response at the target-specific microring exposed to the different RT-products in 
different experiments.  Importantly, sensors only show responses at the when exposed to the 
specifically-targeted miRNA RT product, demonstrating the potential for multiplexed miRNA 
measurements. 
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Figure 3.6:  Microring sensor response of total RNA profiling from lung and brain tissue. 
Microrings previously functionalized with 8 different capture probes (7 complimentary to a 
specific miRNA target and one off target control) were subjected to the optimized assay.  The 
resulting shifts were quantitated by taking the difference before and after 4-CN oxidation. (A) 
Binding curves obtained when using an input of 1 μg of total RNA isolated from lung tissue. (B) 
Binding curves obtained when using an input of 1 μg of total RNA isolated from brain tissue. 
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Figure 3.7: A) Comparison of the concentrations for each of the 7 targets (n=8-16 technical 
replicates). B) Comparison of miRNA expression profiles obtained using microrings and RT-
qPCR normalized to miR-26a expression. 
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 Sequence 
hsa miRNA-26a UUC AAG UAA UCC AGG AUA GGC U 
hsa miRNA-106a AAA AGU GCU UAC AGU GCA GGU AG 
hsa miRNA-21 UAG CUU AUC AGA CUG AUG UUG A 
hsa miRNA-222 AGC UAC AUC UGG CUA CUG GGU CUC 
hsa miRNA-335 UCA AGA GCA AUA ACG AAA AAU GU 
hsa miRNA-219 UGA UUG UCC AAA CGC AAU UCU 
hsa miRNA-29a UAG CAC CAU CUG AAA UCG GUU A 
Conserved region of stem 
loop primer 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTT 
GGA TAC GAC … miRNA specific overhang 
miR-26a SLP Overhang AGCCTATCC 
miR-106a SLP Overhang CTACCTGCA 
miR-21 SLP Overhang TCAACATCAG 
miR-222 SLP Overhang GAGACCCAG 
miR-335 SLP Overhang ACATTTTTCG 
miR-219 SLP Overhang AGAATTGC 
miR-29a SLP Overhang TAACCGATTT 
miR-26a Capture Probe TTC AAG TAA TCC AGG ATA GGC TGT 
miR-106a Capture Probe AAA AGT GCT TAC AGT GCA GGT AGG 
miR-21 Capture Probe TAG CTT ATC AGA CTG ATG TTG AGT 
miR-222 Capture Probe AGC TAC ATC TGG CTA CTG GGT C 
miR-335 Capture Probe TC AAG AGC AAT AAC GAA AAA TGT GT 
miR-219 Capture Probe TGA TTG TCC AAA CGC AAT TCT GT 
miR-29a Capture Probe TAG CAC CAT CTG AAA TCG GT 
Control Capture Probe /5AmMC12/CTACAAGTGCCTTCACTGCAGT 
Stem Loop Primer 
Compliment 
5’-biotinTEG-ATACCTCGGACCCTGCACT-3’ 
Table 3.1: Summary of nucleic acid sequences 
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Target Assay ID 
miR-26a 000405 
miR-106a 002169 
miR-21 000397 
miR-222 000525 
miR-335 000546 
miR-219 000522 
miR-29a 002112 
Table 3.2: RT-qPCR assay IDs for miRNA targets (sequences not provided by vendor) 
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Step Flow Rate (μL/min) Duration (min) 
Hybridization Buffer 30 3 
RT Product 15 14* 
Hybridization Buffer 30 1 
0.05% PBST 30 5 
SA-HRP (4 μg/mL) 30 3 
0.05% PBST 30 2 
4-CN 30 9 
0.05% PBST 30 3 
*For total RNA profiling, the duration was increased to 25 minutes, which improved 
hybridization specificity. 
Table 3.3: Details on fluid flow conditions used in the assay 
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Target Brain Sample C(t) Std. Dev. Lung Sample C(t) Std. Dev. 
miR-26a 21.92 0.23 17.46 0.03 
miR-106a 26.33 0.11 19.54 0.04 
miR-21 24.78 0.13 17.04 0.05 
miR-222 29.00 0.16 23.33 0.03 
miR-335 24.78 0.05 20.01 0.03 
miR-219 27.56 0.05 34.72 0.28 
miR-29a 22.52 0.12 17.74 0.03 
Table 3.4: The brain and lung RNA samples used in Figure S3 were subjected to RT-qPCR 
analysis.  Each sample was reverse transcribed (100 ng input) and subjected to PCR in triplicate. 
Outlined in the table are the average C(t) values and the standard deviation of the measurements 
for individual miRNA targets. 
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Chapter 4 
 
AN OPTICAL PLATFORM FOR THE LABEL-FREE 
DETECTION OF MULTIPLE MICRORNAS FROM 
TUMOR TISSUE ISOLATES 
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4.1 Introduction 
The landscape of biomedical research is rapidly changing, and it is now well accepted 
that multiplexed diagnostics can significantly improve our understanding of disease onset and 
progression. One of the important consequences of multiplexed analysis is a better understanding 
of the role of microRNA (miRNA) molecules and their interconnectivity with proteins to 
regulate biological functions.
1
 Dysregulation of these interactions has been shown to have 
profound implications in a wide range of pathological conditions.
2-6
 
Unfortunately, current clinically relevant platforms suffer from technological gaps that 
have hindered the translation of miRNA-based diagnostics to the clinic.
7
 Specifically, qRT-PCR 
methods are incredibly sensitive, relatively rapid, and cost effective; however they can only 
measure levels of one miRNA per assay, thus requiring multiple sample aliquots to profile a 
panel of targets. Microarrays, are well-suited for multiplexed analyses, but are typically slow, 
less sensitive, and more expensive. Next-generation sequencing is also amenable to multiplexed 
analyses and identifies known and unknown miRNA sequences, but requires complex processing 
steps and presents challenges with time-intensive data analysis.  Given bioinformatic approaches 
that narrow down global expression profiles to reveal subsets of the most informative 
biomarkers,
8
 the development of a meso-plex detection platform looms as an important goal for 
the clinical translation of miRNA diagnostics. 
We believe that silicon photonic microring resonators, a class of high-Q optical sensors,9 
are a viable option to facilitate meso-plex diagnostics in the clinic.  These sensors are a 
multiplexable, array-based technology that have been applied to a range of biomolecular 
detection applications.10-13 While these sensors have been discussed in detail,14 they rely on 
changes in refractive index near the surface of the sensor, which is induced by biomolecular 
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binding that displaces water.  This change in refractive index causes a shift in the resonant 
wavelength of the sensor which is directly proportional to the amount of the surface bound 
biomolecules and the solution phase analyte concentration.  These sensors have previously been 
used for detection of microRNAs in label-free,15 capture-agent-enhanced,16 and enzymatic-label-
enhanced formats.17  While these studies show the promise of multiplexed miRNA analysis, they 
suffer from large input requirements, lengthy processing steps, or sensitivity issues that preclude 
them from use in a clinical setting. 
In this study, we improve upon these previously reported strategies.  This assay leverages 
the abilities of asymmetric PCR (aPCR)
18,19
 combined with silicon photonic microring resonators 
to make rapid and cost-effective measurements in a small footprint.  When compared to previous 
efforts, we show this assay reduces the required sample amount from micrograms to nanograms, 
increases multiplexing capabilities, and provides a time to result within hours.  Importantly, we 
are the first group to develop a robust miRNA detection platform using aPCR and show its utility 
by simultaneously profiling 9 miRNAs from multiple brain cancer patients. 
4.2 Experimental 
4.2.1 Materials 
All nucleic acid sequences (stem loop primers, PCR primers, synthetic RNA, etc.) were 
synthesized from Integrated DNA Technologies (IDT; Coralville, IA) and are listed in Table 4.1. 
The TaqMan® microRNA Reverse Transcription Kit and the Platinum® Multiplex PCR Master 
Mix were purchased from Thermo Fisher. All buffers and dilutions were prepared in nuclease 
free Ultrapure distilled water (Invitrogen). 1X Phosphate Buffer Saline (PBS) buffer was 
obtained from Lonza and was used in the reconstitution of the DNA capture probes. For the 
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functionalization of the chips, 3-(Aminopropyl)triethoxysilane (APTES) and 
bis(sulfosuccinimidyl)suberate (BS3) were obtained from Thermo Fisher Scientific. For the 
hybridization steps, a high stringency hybridization buffer was made in 50 mL batches 
containing 15 mL of formamide (Fisher), 1 mL 10% sodium dodecyl sulfate (Fisher), 10 mL 
20X saline-sodium phosphate buffer (Invitrogen), 6 mL 0.25 M ethylenediaminetetraacetic acid 
(Invitrogen) and 2.5 mL 50X Denhardt’s solution (Invitrogen). RT-qPCR assays were purchased 
from Thermo Fisher, and target specific assay IDs are listed in Table 4.2.  
4.2.2 Instrumentation 
Microring sensor arrays and measurement equipment were purchased from Genalyte, Inc. 
(San Diego, CA). The chips were made using standard photolithography and etching techniques. 
After patterning, the wafers were covered by a polymer cladding and diced into individual chips 
containing 132 individual microring resonator sensors.  After polymer removal, the surface is 
ready to be functionalized and used in hybridization experiments. To perform hybridization 
experiments, the ring array is covered with a microfluidic Mylar Gasket and Teflon lid.  The 
Mylar Gasket directed fluid flow into two defined flow chambers.  Integrated pumps were used 
to perform all liquid handling steps, and the specifics of those steps are listed in Table 4.3.  
Resonant wavelengths for each microring were determined by coupling a tunable laser 
source into an adjacent linear waveguide via on-chip grating couplers. The laser output was then 
swept through an appropriate spectral window and the light intensity at the end of the linear 
waveguide was used to determine the resonance wavelength. This process was then serially 
repeated for each ring in the array, and the resultant shifts in resonance as a function of time 
were recorded. 
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The resonance condition that is supported by the microring resonators is governed by the 
following equation: 
mλ = 2πrn
eff
 
where m equals a nonzero integer, λ is the wavelength of propagating light, r is the microring 
radius, and neff is the effective refractive index of the local microring environment. Boundary 
conditions of light propagating in linear waveguides via total internal reflectance result in an 
evanescent field extending into a region very close to the ring surface. Interactions between the 
evanescent field and the local environment cause a change in the resonant wavelength, which is 
then monitored by the optical scanning instrumentation. Therefore, the binding of higher 
refractive index biomolecules and accompanying displacement of water results in a resonance 
shift to longer wavelengths: a positive shift that is listed in units of Δ picometers (Δpm). 
4.2.3 Surface Functionalization 
Surface functionalization was performed using one of two protocols:  spotting by hand or 
spotting with high-resolution instrumentation. 
(1) Hand spotting was used to perform the validation experiments and calibration curves.  Prior 
to chip functionalization, chips were cleaned with a Piranha solution (70% Sulphuric Acid/30% 
Hydrogen Peroxide) for 30 seconds at 60ºC. CAUTION: Piranha is a dangerous solution and 
needs to be handled with caution.  Then, the chips were rinsed with water and dried with 
nitrogen. Once dried, chips were immersed in acetone for 2 minutes, followed by the surface 
silanization with a 5% APTES solution (diluted in acetone) for 4 minutes. After silanization, the 
chips were immersed in acetone and isopropanol for 2 minutes each. All steps were completed 
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with continued shaking. Chips were rinsed with water and nitrogen dried to complete the 
silanization process. Next, 20 μL of a freshly prepared BS3 solution (2.85 mg/mL in acetic acid) 
was placed on the microring array for 3 minutes.  BS3 served as the linker between the amine 
groups of the silanized surface and the amino-functionalized nucleic acid capture probes. After 
BS3 incubation, the chips were dried with nitrogen, and the final step consisted of spotting 
approximately 260 nL of 200 μM 5’amino functionalized DNA captures probes onto discrete 
microring sensors.  The chips were then left to incubate for at least 4 hours in a humidity 
chamber.   
(2) Spotting using high resolution instrumentation was used to complete the cross reactivity 
studies and patient sample profiling.  The only experimental difference when using this 
instrumentation was surface salinization with a 1% APTES solution, a lower concentration of 
BS3 (1 mg/mL), and a lower concentration of the DNA capture probes ( 100 μM).  All 
incubation steps and times were identical.  
4.2.4 Reverse Transcription - Asymmetric PCR Amplification 
Reverse transcription reactions were conducted using the TaqMan microRNA Reverse 
Transcription Kit. Each 15 μL reaction volume contained 4.16 μL of nuclease free water, 1.5 μL 
of 10X RT buffer, 1 μL of Multiscribe™ RT enzyme (50 U/ μL), 0.19 μL of RNase inhibitor (20 
U/ μL), 0.15 μL dNTP mix (100 mM), 5 μL of RNA sample and 3 μL of the reverse transcription 
primer. The concentration of the stem loop primer was 20 μM or all experiments, except for the 
data presented in Figure S1 where 200 μM was used. The thermal profile was completed 
following the manufactures protocol: 16º C (30 min), 42º C (30 min), and 85ºC (5 min).  
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Asymmetric PCR was performed using the Platinum® Multiplex PCR Master Mix. Each 50 μL 
reaction volume was composed of 14 μL nuclease free water, 25 μL of Platinum® Multiplex 
PCR Master Mix, 5 μL of each primer and 1 μL of the reversed transcribed product. The 
concentration of the forward primer (the limiting primer) was 2 μM while the concentration of 
the reverse primer was 200 μM. The reactions were incubated at 95 ºC for 2 min, followed by 
cycles of 95 ºC for 30 s, 56ºC for 1 min 30 s and 72 ºC for 1 min. 
4.2.4 Data Analysis 
Data was analyzed with Origin Pro 9.0 and completed in three steps: (1) calculation of the 
hybridization response, (2) determination of C(t) values, and (3) heat map compiling. 
(1) Hybridization response calculation 
Prior to plotting hybridization induced shifts, sensor traces were corrected for temperature and 
instrument drift by using a series of reference sensors.  Afterwards, microring hybridization 
traces were plotted.  Net shifts of the aPCR product hybridization were calculated by subtracting 
the signal of the buffer step after hybridization (22 minutes) from the baseline buffer signal at 5 
minutes.  After net shifts are calculated, the shift value of the miRNA target of interest is then 
subtracted from an off target control cluster. 
(2) C(t) value determination  
The calculated net shift induced by DNA binding was ploted versus the PCR cycle for every 
target. A linear trace was then used to connect the data points.  The threshold cycle was 
calculated by determining where the linear trace crossed the threshold shift value, which was 
calculated by taking 40% of the maximum signal. 
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(3) Heat map 
The heat map was produced by subtracting the C(t) value of the disease sample from the healthy 
sample.  The resulting values are plotted in Table 4.4 using a log 2 scale.  Positive numbers 
represent over expression in tumor tissue and negative numbers represent under expression in 
tumor tissue.  
4.2.5 RT-qPCR 
For RT-PCR validation experiments, 10 ng of total RNA was used. Reverse transcription 
was performed using the TaqMan microRNA Reverse Transcription Kit (Life Technologies) and 
miRNA-specific stem loop primers, listed in Table S2. Reverse Transcription was carried out 
using the following thermal profile: 16°C (30 min), 42°C for (30 min), and 85°C (5 min).  RT 
products were subjected to quantitative PCR in triplicate using PCR primers from the same 
miRNA Assay Kit.  The reaction was performed at 95°C (10 min), followed by 40 two-step 
cycles of (1) 95°C for 15 s and (2) 60°C for 1 min.  All quantitative PCR work was done using 
an Applied Biosystems 7900HT Fast Real-Time PCR System. All procedures and reactions were 
carried out according to the protocols provided by the manufacturer. 
4.3 Discussion 
The schematic of the developed protocol is seen in Figure 4.1.  First, total RNA is 
extracted from a sample of interest (i.e. cell culture, bodily fluids, tumor tissue, etc.).  miRNA 
targets are then reverse transcribed (RT) using stem loop primers specific to each target.
20
  Next, 
the RT products are amplified via asymmetric PCR since traditional PCR is not amenable to 
surface hybridization-based assays due to the fact that it produces double stranded DNA 
(dsDNA).  Asymmetric PCR selectively produces single stranded DNA (ssDNA) products by 
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using an excess of the forward PCR primer.
18,19
 Here, we use a 100 fold excess. As shown in 
Figure 4.1C, dsDNA is produced until the limiting PCR primer is exhausted; afterwards, ssDNA 
production occurs in subsequent thermal cycles by extension of the primer in excess.  After 
thermal cycling is complete, the PCR product is diluted in a high stringency hybridization buffer 
and flowed across a microring array, where hybridization to complimentary, surface-bound 
capture probes occurs.  As the hybridization takes place, it causes a shift in the resonant 
wavelength of the microring sensors.  
To validate this approach, we first designed primer sets whose sequences are included in 
Table 4.1.  Next, we show that this assay can detect varying input amounts of target miRNAs 
(Figure 4.2).  As expected, an increase in the number of thermal cycles leads to lower amounts of 
RT being amplified to a detectable level.  We mimicked qPCR quantitation protocols to 
determine the dynamic range and linear amplification profile of this assay.  To complete these 
experiments, we reverse transcribed varying input concentrations of a synthetic let-7f RNA 
sequence.  The reverse transcription products were thermally cycled, and samples were 
introduced to a microring surface after a varying number of cycles.  The results are plotted in 
Figs. 4.2A and B.  In Figure 4.2A, we used a logistic fit to produce binding curves for the 
respective input concentrations.  We then took the second derivative of the binding curves and 
set the threshold value where the second derivative is equal to zero.  In order simplify 
quantification, we also developed a protocol to manually determine the threshold value.  As 
shown in Fig. 4.2B, we first determined a threshold shift value by calculating forty percent of the 
maximum shift value.  After interpolating a line between all data points, we determine the cycle 
at which the interpolated lines cross the threshold relative shift value.  Results for both 
quantitation methods are shown in Figure 4.2C and show linearity over 6 orders of magnitude. 
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We conducted similar experiments for all 9 miRNA targets with each one producing linear 
results (Fig. 4.3).  Lastly, we show the target specificity of the platform in Figure 4.2D by 
combining all capture probes onto one sensor surface and introducing RT-aPCR products from 
individual target miRNA sequences.  Each trace shows a specific response using a 200 nM 
sample that is thermally cycled for 20 cycles.  Importantly, these results show limited non-
specific response for all targets. 
Next, we used the assay to profile 9 miRNAs extracted from tumor tissues and compared 
the expression profiles to that obtained from a commercially available pooled “healthy” total 
RNA sample.  Representative data is shown in Figure 4.4A-B from the healthy reference sample 
and a glioblastoma (GBM) patient.  C(t) values were calculated, using the manual method 
outlined above.  To validate these results we profiled the same RNA samples using RT-qPCR and 
the correlation is shown in Figure 4.4C.  While the overall correlation generally trends in the 
same direction, we attribute some of the inconsistencies to differing primer sets and PCR master 
mixes as well as other sample handling inconsistencies (i.e. pipetting and freeze-thaw cycles). 
Lastly, the assay was used to profile miRNAs from 20 brain tumor patients (Fig. 4.4D).  
Patient specifics are listed in Table 4.5.  After determining fold changes between the disease and 
healthy samples using the microring platform,
21
 trends seen in this data can be confirmed with 
studies from the literature.  The fold change values of the heat map are shown in Table 4.6.  For 
example, miRs-10b, 155, and 222 are known to be upregulated in glioma tissue and the majority 
of patients show the same pattern.
22-24
  Alternatively, miRs-34a and 29a have been shown to be 
downregulated in glioma tissue and a number of patients profiled here exhibit similar trends.
25,26
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4.4 Conclusions  
In sum, we successfully developed a platform that enables the multiplexed detection of 
miRNAs.  By leveraging the ability of asymmetric PCR to produce single stranded PCR products 
and silicon photonic microring resonators to detect the products in a highly-sensitive and label 
free fashion, we show that this platform can product linear calibration curves similar to those 
obtained using conventional qPCR and on the same time scale.  This report provides the 
foundation that we aim to expand upon in the future.  Future studies will aim to increase 
multiplexing capabilities, expand into different classes of RNA molecules, and improve 
automation capabilities. 
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4.5 Figures and Tables 
 
Figure 4.1: (A) Overview of aPCR-microring assay from RNA isolation to using miRNA 
profiles to make biological conclusions. (B) Mechanism of reverse transcription-asymmetric 
PCR amplification. (C) Schematic showing DNA amplification as cycle numbers increase.  
Importantly, there is a shift from double stranded DNA (dsDNA) production to ssDNA 
production when the limiting primer in the primer set is exhausted.  Corresponding to this change 
is an increase in signal detected by the microring platform as these ssDNA amplicons hybridize 
to the sensor surface. 
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Figure 4.2: (A) Amplification plot used to quantitate let-7f using the second derivative method. 
(B) Amplification plot used to quantitate let-7f using the second manual method.  (C) Calibration 
curve for each method (respectively, slope = -3.41 and -3.37 and R
2
 values = 0.96 and 0.95, 
respectively).  (D) Plot showing specificity of a capture probes on a single sensor array. 
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Figure 4.3: Amplification Validation of miRNA Targets.  In order to prove linear amplification 
of all miRNA targets, 200 nM, 20 nM, and 2 nM samples of each target were subjected to the 
aPCR-microring assay using a stem loop primer concentration of 200 μM.  The results validated 
the designed primer sets by displaying linear amplification profiles. 
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Figure 4.4: (A-B) Results obtained when using a 10 ng input of a healthy control and glioma 
grade IV total RNA sample, respectively, and subjecting it to varying cycles of the aPCR-
microring assay. (C) Comparison of fold changes using the microring platform and qRT-PCR. 
(D) Heat map showing expression profiles from patient samples. 
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Figure 4.5: Plots used to calculate C(t) values for each sample of interest. 
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Figure 4.5 (cont.) 
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Figure 4.5 (cont.) 
 
128 
 
25 30 35 40
-20
0
20
40
60
80
100
120
R
e
la
ti
v
e
 S
h
if
t 
(
p
m
)
Cycle Number
 let-7f
 miR-10b
 miR-29a
 miR-34a
 miR-124a
 miR-155
 miR-219
 miR-222
 miR-335
Patient 31
 
25 30 35 40 45
0
30
60
90
120
R
e
la
ti
v
e
 S
h
if
t 
(
p
m
)
Cycle Number
 let-7f
 miR-10b
 miR-29a
 miR-34a
 miR-124a
 miR-155
 miR-219
 miR-222
 miR-335
Patient 32
 
30 35 40 45
-20
0
20
40
60
80
100
120
R
e
la
ti
v
e
 S
h
if
t 
(
p
m
)
Cycle Number
 let-7f
 miR-10b
 miR-29a
 miR-34a
 miR-124a
 miR-155
 miR-219
 miR-222
 miR-335
Patient 33
 
Figure 4.5 (cont.) 
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 Sequence 
hsa miRNA-let7f UGAGGUAGUAGAUUGUAUAGUU 
hsa miRNA-219 UGAUUGUCCAAACGCAAUUCU 
hsa miRNA-10b UACCCUGUAGAACCGAAUUUGUG 
hsa miRNA-29a UAGCACCAUCUGAAAUCGGUUA 
hsa miRNA-335 UCAAGAGCAAUAACGAAAAAUGU 
hsa miRNA-124a UAAGGCACGCGGUGAAUGCC 
hsa miRNA-222 AGCUACAUCUGGCUACUGGGUCUC 
hsa miRNA-34a UGGCAGUGUCUUAGCUGGUUGU 
hsa miRNA-155 UUAAUGCUAAUCGUGAUAGGGGU 
Conserved Stem Loop 
Primer 
GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGA
T…miRNA specific overhang 
miR-let7f SLP overhang AACTATAC 
miR-219 SLP overhang AGAATTG 
miR-10b SLP overhang CACAAATTC 
miR-29a SLP overhang TAACCG 
miR-335 SLP overhang ACATTTTT 
miR-124a SLP overhang GGCATTC 
miR-222 SLP overhang GAGACCC 
miR-34a SLP overhang ACAACCA 
miR-155 SLP overhang ACCCCT 
Conserved reverse primer  GTGCAGGGTCCGAGGTATTCGCACTGGATACGAC 
miR-let7f PCR forward 
primer 
CGCGCTGAGGTAGTAGATT 
miR-219 PCR forward 
primer 
CGCGTGATTGTCCAAACG 
miR-10b forward primer GCGTACCCTGGTAGAACC 
miR-29a forward primer CGCTAGCACCATCTGAAAT 
miR-335 forward primer CGCGTCAAGAGCAATAACG 
miR-124a forward primer CGTAAGGCACGCGGT 
miR-222 forward primer CGAGCTACATCTGGCTACT 
miR-34a forward primer GCGTGGCAGTGTCTTAGC 
miR-155 forward primer CGCGTTAATGCTAATCGTGAT 
Table 4.1:  Summary of nucleic acid sequences 
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Target Assay ID 
miRNA-let7f 000382 
miRNA-219 000522 
miRNA-10b 002218 
miRNA-29a 0022112 
miRNA-335 000546 
miRNA-124a 001182 
miRNA-222 000525 
miRNA-34a 000426 
miRNA-155 002623 
Table 4.2:  Summary of RT-qPCR assay IDs 
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Step Flow Rate (μL/min) Duration (min) 
Hybridization buffer 20 5 
RT-PCR product 20 15 
Hybridization buffer 20 5 
Table 4.3:  Details on fluid flow conditions 
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 Healthy Brain 
RNA sample C(t) 
Standard 
Deviation 
Patient 1 RNA 
sample C(t) 
Standard 
deviation 
let-7f 26.95 0.03 29.96 0.03 
miRNA-219 28.89 0.04 28.14 0.02 
miRNA-10b 33.79 0.16 20.56 0.05 
miRNA-29a 22.75 0.02 27.87 0.03 
miRNA-335 29.19 0.06 27.32 0.06 
miRNA-124a 23.88 0.02 29.90 0.04 
miRNA-222 24.69 0.03 27.42 0.02 
miRNA-34a 26.95 0.02 27.33 0.06 
miRNA-155 30.85 0.13 29.39 0.03 
Table 4.4: Samples (10 ng) from the “healthy” pooled cohort and Patient 1 were subjected to 
qRT-PCR analysis as outlined above.  This data provides the C(t) values used to compile fold 
change values. 
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Patient Sample Gender Age Cancer type 
1 M 62 Glioma – grade IV 
2 M 42 Glioma – grade IV 
3 M 47 Glioma – grade IV 
6 F 52 Glioma – grade II 
7 F 67 Glioma – grade IV 
9 F 75 Glioma – grade IV 
10 F 29 Glioma – grade III 
12 F 48 Glioma – grade IV 
16 F 37 Glioma – grade III 
18 F 35 Glioma – grade III 
20 M 26 Glioma – grade IV 
23 M 38 Glioma – grade IV 
24 F 67 Glioma – grade IV 
25 M 25 Glioma – grade III 
26 F 27 Glioma – grade II 
28 M 30 Glioma – grade III 
29 M 51 Glioma – grade IV 
31 F 63 Meningioma – grade I 
32 F 69 Glioma – grade IV 
33 F 74 Meningioma – grade I 
Table 4.5: Patient information 
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Patient  let 7f miR-
10b 
miR-
29a 
miR-
34a 
miR-
124a 
miR-
155 
miR-
219 
miR-
222 
miR-
335 
1 0.83 0.68 -0.92 -1.18 -2.76 -1.81 -1.19 -1.78 -1.27 
2 0.73 0.55 0.09 0.05 0.12 -0.7 0.61 3.02 0.08 
3 0.8 0.88 -0.14 -0.27 0.91 2.42 0.71 1.45 0.07 
6 -0.03 0.7 -1.65 -2.97 -0.08 0.73 0.53 1.7 0.07 
7 -3.1 -2.95 -2.63 -2.44 0.11 1.29 0.27 8.05 -6.21 
9 -3.38 -3.72 -3.31 -2.62 -0.02 1.96 -0.01 1.87 0.07 
10 -3.09 -1.35 -2.89 -2.51 -1.89 1.03 -0.3 0.04 0.1 
12 -2.6 0.23 -2.22 -0.74 0.81       2.98 0.84 2.67 -0.03 
16 -1.71 -0.43 -1.8 -2.85 -2.02 1.68 0.05 2.07 -2.25 
18 1.21 1.43 1 1.66 1.51 3.6 2.86 4.32 -0.68 
20 2.35 3.76 3.9 1.15 4.17 8.02 6.86 9.44 1.95 
23 3.36 5.68 5.42 2.1 6.3 9.08 8.14 11.67 0.91 
24 0.73 0.94 1.08 0.76 2.09 3.7 3.79 3.9 -2.51 
25 0.69 1.46 1.38 0.88 2.23 3.14 1.54 3.15 -7.03 
26 0.99 1.23 1.19 0.61 0.97 -0.38 -1.24 0.86 -6.44 
28 2.73 5.46 1.97 0.32 6.23 8.51 3.54 6.45 5.05 
29 0.11 0.83 0.17 2.35 -0.51 3.73 4.32 7.05 -4.29 
31 1.94 1.68 2.6 -1.37 -1.76 4.4 5.38 9.48 -1.73 
32 1.33 0.98 1.16 -2.98 0.31 4.59 -0.13 6.27 -3.55 
33 0.37 0.86 0.83 -1.21 -1.1 4.38 5.01 7.85 -1.36 
Table 4.6: Fold changes presented in heat map (log2) 
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Chapter 5 
 
COMBINING PCR-BASED ENZYMATIC 
AMPLIFICATION WITH SILICON PHOTONIC 
MICRORING RESONATORS FOR THE DETECTION OF 
LNCRNAS FROM LOW INPUT HUMAN SAMPLES 
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5.1. Introduction  
In recent years, the attention given to multiplexed biomolecular analysis has been 
increasing because of its potential to revolutionize areas of human health, such as diagnosis, 
prognosis and therapeutic selection. The discovery of potential biomarkers for different diseases 
has been one of the main drivers in the development of multiplexed diagnostic analysis. Among 
the different types of biomarkers, RNA molecules have risen in importance thanks to the use of 
next generation sequencing and the resulting insights in cell signaling regulation.
1
 Furthermore, 
accumulating reports noting the differential expression of non-coding RNAs (ncRNAs) in 
disease suggest that they are potential candidates as biomarkers for the development of new 
diagnostic devices and therapies.
2
 
ncRNAs can be defined as those transcripts that do not encode any protein. ncRNA can 
be divided into two major groups based on their length: small non coding RNAs (< 200 
nucleotides), which include Piwi-interacting RNAs, small interfering RNAs and microRNAs 
(miRNAs) and long non coding RNAs, lncRNAs, those that are longer than 200 nucleotides.
3
 
Since the discovery of the first well studied imprinted lncRNA, H19,
4
 there have been a plethora 
of studies identifying more of these transcripts, and these studies relate expression of lncRNAs to 
different biological functions.
5-7
 Particularly in cancer, researchers have focused more of their 
effort in understanding how these transcripts have roles as drivers of tumor suppressive and 
oncogenic functions.
8,9
 
As an illustration of the importance of using multiplexed lncRNA diagnostic panels, 
scientists have made progress connecting differential expression of these transcripts in cancers 
like glioma and glioblastoma with the objective of identifying different subtypes and malignant 
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behaviors in these tumors.
10,11
 In the first study, microarrays were used to identify subtype and 
grade of glioma based on lncRNA signatures.  Here, they were able to pare down their biopanels 
from around 2,000 potential lncRNA targets to around 25 to 50 targets. In the second study, 
based on in silico analysis, the researchers mined data from The Cancer Genome Atlas and 
developed a signature of six lncRNAs that allowed them to predict survival in glioblastoma. 
To translate these panels into the clinic the main techniques for the detection of these 
transcripts, typically qRT-PCR, hybridization assay such as microarrays, and RNA 
sequencing,
12,13
 need to be improved.  These techniques are robust, sensitive and, in the case of 
RNA sequencing, allow the discovery of new lncRNAs in the genome. However, they either 
look at one target per sample, follow burdensome experimental protocols, or collect an 
unnecessary amount of data to analyze relevant RNA-based biopanels. One of the challenges for 
biosensor community is to develop multiplexed technologies to facilitate the detection of similar 
biopanels as those previously outlined in a sensitive, efficient, and affordable manner.  
In response to this challenge, we have developed a silicon photonic microring resonator 
technology that enables the multiplexed detection of a host of biomolecules. The specifics of the 
instrumentation have been discussed in detail previously.
14,15
. The sensing principle is based on 
the change of refractive index near the surface of the rings, which occurs when biomolecules 
selectively bind to receptors on the microring surface. One of the advantages of this platform is 
the ability of sensing without the addition of fluorescent or enzymatic tags. Other advantages are 
the ability to fabricate sensing semiconductor chips in parallel arrays which enables multiplexed 
detection. The promise of these sensors have been used previously for the study of proteins
16-18
 
as well as nucleic acids, including mRNAs
19
 and Bailey, 2012), tmRNAs
20
 and  miRNAs
21,22
. 
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In this study, we develop an assay for the detection of long non coding RNAs. This assay 
relies on asymmetric PCR (aPCR) to selectively produce single stranded DNA (ssDNA) products 
by using an unequimolar primer ratio.
23,24
 We then use microring arrays to detect these PCR 
process at different cycles, closely mimicking the process of qPCR. Compared to previous long 
RNA detection efforts from our lab,
19
 we have decreased input amounts from micrograms to 
nanograms, incorporated an internal control mRNA sequence, and studied an important disease-
relevant class of RNA molecules, lncRNA. We use this assay to study the expression of two 
lncRNA sequences and an internal control mRNA in reference samples from lung and brain as 
well as a glioblastoma cell line. We also compare the obtained expression profiles to previous 
literature findings and subject the same RNA samples to qRT-PCR analysis to validate this 
platform and demonstrate its potential to provide a new alternative for the detection of these 
transcripts in both clinical and research settings.  
5.2. Experimental 
5.2.1 Materials 
All nucleic acid sequences (primers and capture probes) were synthesized from 
Integrated DNA Technologies (IDT; Coralville, IA). The TaqMan® microRNA Reverse 
Transcription Kit, the Platinum® Multiplex PCR Master Mix and the SYBR® Select Master Mix 
were purchased from Thermo Fisher. All buffers dilutions, DNA primer reconstitution and DNA 
primer dilutions were prepared in nuclease-free Ultrapure distilled water (Invitrogen). 1X 
Phosphate-Buffered Saline (PBS) was obtained from Lonza and was used in the reconstitution of 
the oligonucleotide capture probes. For the functionalization of the microring chips, 3-
Aminopropyl)triethoxysilane (APTES) and bis(sulfosuccinimidyl)suberate (BS3) were obtained 
from Thermo Fisher Scientific. For all hybridization steps, a high stringency hybridization buffer 
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was made in 50 mL batches containing 15 mL of formamide (Fisher), 1 mL 10% sodium dodecyl 
sulfate (Fisher), 10 mL 20X saline-sodium phosphate buffer (Invitrogen), 6 mL 0.25 M 
ethylenediaminetetraacetic acid (Invitrogen) and 2.5 mL 50X Denhardt’s solution (Invitrogen). 
5.2.2 RNA Sample Preparation 
Total RNA was extracted from GBM6 cell lines lysates with a miRNeasy® Mini kit 
(Quiagen) using manufacture’s protocol. After extraction, total RNA was assessed for purity and 
quantity using a ThermoFisher Nanodrop UV−vis spectrometer and stored at −80°C until further 
use. The Brain and Lung Reference RNA samples were obtained commercially from Thermo 
Fisher Scientific and stored at -80°C until further use. 
5.2.3 Amplification Primers and Capture Probe Design 
Specific primers and capture probes for the amplification and detection of the human 
lncRNAs MALAT1 and KIAA0495 and the internal control β-actin were designed using 
sequence annotations from Genbank (NCBI) and the Primer-Blast platform (NCBI). In order to 
observe the secondary structure, we used the Dinamelt web server (Markham and Zuker, 2005). 
Sequences of the primers and capture probes can are listed in Table 5.1.  
5.2.4 Silicon Photonic Microring Resonator Instrumentation 
Microring sensor arrays and measurement equipment were purchased from Genalyte, Inc. 
(San Diego, CA), and the detection mechanism has been discussed in detail previously (Iqbal et 
al., 2010; Washburn et al., 2010). The chips were made on silicon on insulator wafers by 
photolithography and etching techniques. After patterning, the wafers were covered by a polymer 
cladding and diced into individual chips measuring 6 mm x 4 mm and containing 132 individual 
microring resonator sensors.  After polymer removal, the surface is ready to be functionalized 
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and used in hybridization experiments. To perform hybridization experiments, the microring 
array is covered with a microfluidic Mylar gasket and Teflon lid.  The Mylar gasket directs fluid 
flow into two defined flow channels.  Integrated pumps were used to perform all liquid handling 
steps, and the specifics of those steps are listed in Table 5.2. 
5.2.5 Surface Functionalization of the Microring Resonators 
Sensor chips were immersed in acetone for 2 min, followed by the surface silanization 
with 5% APTES (diluted in acetone) for 4 min. After silanization, the chips were immersed in 
acetone and isopropanol for two minutes each. All steps were completed with continuous 
shaking. Chips were rinsed with water and nitrogen dried to complete the silanization process. 
Next, 20 uL of a freshly prepared BS3 solution (2.85 mg/mL in acetic acid) was placed on the 
microring array for 3 minutes. After BS3 incubation, the chips were dried with nitrogen, and the 
final step consisted of spotting approximately 260 nL of 200 μM 5’amino functionalized DNA 
captures probes onto discrete microring sensors.  The chips were then left to incubate overnight 
in a humidity chamber.   
5.2.6 Reverse Transcription – Asymmetric PCR 
Reverse transcription reactions were conducted using the TaqMan microRNA Reverse 
Transcription Kit (ThermoFisher). Each 15 μL reaction volume contained 4.16 μL of nuclease 
free water, 1.5 μL of 10X RT buffer, 1 μL of Multiscribe™ RT enzyme (50 U/ μL), 0.19 μL of 
RNase inhibitor (20 U/ μL), 0.15 μL dNTP mix (100 mM), 5 μL of RNA sample (40 ng RNA 
total) and 3 μL of reverse transcription primer. The concentration of the reverse primer was 200 
μM when only one transcript was reversed transcribed and 66 μM when three transcripts were 
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reverse transcribed. The thermal profile was completed following the manufactures protocol: 65º 
C (5 min), 4º C (2 min), 42º C (30 min), and 85ºC (5 min).  
Asymmetric PCR was performed using the Platinum® Multiplex PCR Master Mix 
(Thermo Fisher). Each 50 μL reaction volume was composed of 14 μL nuclease free water, 25 
μL of Platinum® Multiplex PCR Master Mix, 5 μL of each primer and 1 μL of the reversed 
transcription product. The concentration of the forward primer (the limiting primer) was 2 μM 
while the concentration of the reverse primer (the excess primer) was 200 μM. The reactions 
were incubated at 95 ºC for 2 min, followed by cycles of 95 ºC for 30 s, 58ºC for 45 s and 72 ºC 
for 30 s.  To profile the amplification process, PCR samples were taken from the thermocycler at 
different cycle numbers (i.e. every two cycles or every 5 cycles). 
5.2.7 Sensor Fluidics and Sample Introduction 
PCR samples (50 μL) were diluted in 350 μL of the hybridization buffer described in the 
Materials section. The hybridization of the samples was carried out at room temperature, passing 
the fluids above the chip surface at a rate of  20 μL/min for 13 min. After the hybridization of 
each cycle sample, the chip was rinsed with the hybridization buffer for 2 min. The full 
hybridization assay protocol can be seen in the Table 5.2.  
5.2.8 Quantitative PCR 
Real time quantitative PCR was performed using a 7900HT Fast Real-Time PCR system 
(ThermoFisher). Reverse transcription protocols were identical to those listed in the Reverse 
transcription - asymmetric PCR section.  Each reaction contained 5.6 μL of nuclease free water, 
10 μL of  SYBR® Select Master Mix, 2 μL of each primer (2 μM) and 0.4 μL of the reverse 
transcription product. The reaction was initiated at 95 ºC for 2 min, followed by 40 cycles at 95 
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ºC for 15 s followed by 58 ºC for 1 min. The threshold cycle (Ct) was automatically determined 
by the software provided with the instrument.  
5.2.9 Data Analysis 
The microring response was analyzed using OriginPro8 (OriginLab, Northampton, MA). 
The net shift signal from specific rings was corrected for temperature and instrument drift by 
subtracting the signal of control rings from the active rings functionalized with DNA capture 
probes. The data for every target in each sample was detected and averaged using 8 to 16 
replicate measurements on a single chip.  
5.3. Results and Discussion 
In this study, we were able to detect and quantify the expression of two long non coding 
RNAs in three different RNA samples using a microrring resonator platform. The schematic of 
the assay can be visualized in Figure 5.1. In this assay, lncRNAs from different RNA samples 
were reversed transcribed using the target specific primers listed in Table 5.1. After reverse 
transcription, we use asymmetric PCR to selectively produce ssDNA at cycle values that are 
proportional to the initial concentration in the sample of interest. In asymmetric PCR, one of the 
primers is introduced in a limiting concentration and so, when all of the limiting primer is 
extended, only the primer in excess is extended and ssDNA is produced.  This ssDNA product 
can then be detected using microring arrays when they hybridize with complimentary capture 
probes on the microring surface. 
With this assay, we aimed to mimic the quantification process of qPCR, so we collected 
asymmetric PCR samples after varying amounts of thermal cycles. In the case of conventional 
qPCR, double stranded DNA is detected by the addition of SYBR dyes® and fluorescence 
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intensity increases upon double stranded DNA (dsDNA) accumulation. The fluorescent intensity 
is plotted against increasing PCR cycle number and expression profiles can be calculated based 
on the cycle at which fluorescent signal begins. With the aPCR-microring system, we quantitate 
ssDNA accumulation instead of dsDNA accumulation. The microring signal will increase upon 
hybridization of ssDNA targets to complimentary capture probes on the sensor surface. This will 
occur at increased number when compared to traditional qPCR (see Fig. 5.1B). 
5.3.1 Optimization of PCR Amplification and Detection 
An important step in the optimization of the protocol was the design of primer pairs and 
the resulting PCR product. For this purpose, Primer-BLAST was used.
25
 This free online 
platform was very helpful in the designing of primers that contained the desired features and 
prevented the amplification of undesired regions. In addition to primer set design, the preferred 
amplified regions (PCR products) needed to have as little secondary DNA structures as possible 
in order to maximize hybridization to surface bound capture probes. Therefore, once we selected 
a pair of primers, we modeled the secondary structure of the amplified region using the Dinamelt 
web server to ensure that is linear.
26
 An example of this process is included in Figures 5.2-5.3. 
First, this server was used to observe the folding of the molecules to assess secondary structure 
of the PCR product (Figure 5.2). The importance of minimizing secondary structure is shown in 
Figure 5.3.  Primer sets for β-actin were designed with one set producing a PCR amplicon with a 
high degree of secondary structure and another set minimizing secondary structure.  The 
microring signal response is much higher for the primer set minimizing secondary structure. 
After primer design optimization using computational tools, all of the primer pairs were 
validated using gel electrophoresis to ensure that they selectively produce a single band at the 
proper size range (Figure 5.4).  
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Once primer design was optimized, we proceeded to assess the selectivity of the capture 
probes arrayed on the sensor chip surface. In order to do so, we arrayed four capture probes per 
detection channel. A spotting layout and image of the arrayed captures are included in Figure 
5.5. Next, RT-aPCR was carried out for each target using the healthy brain RNA reference 
sample. An initial input of 40 ng RNA was used for the RT, followed by 45 aPCR amplification 
cycles. Samples were individually introduced and allowed to hybridize on a sensor array that 
contained the capture probes for all studied transcripts. The results of these experiments are 
shown in Figure 5.6, where the aPCR products bind to the desired capture probes with limited 
non-specific response. 
After validation of the primer sets and specificity of the microring sensor array, we 
developed a protocol to quantify the expression of target RNAs in a sample.  To complete this, 
aPCR samples were collected after a varying number of thermal cycles.  Then, they were 
sequentially introduced to a single microring array.  An example sensorgram from this type of 
experiment can be seen in Figure 5.7A.  Samples were collected between 25 and 45 cycles, 
because it was observed that there was no detectable signal at cycle numbers lower than 30 and 
further amplification after 45 cycles did not yield an increase in microring signal (data not 
shown). The trace signals observed in Figure 5.7A correspond to the average responses of 16 
rings replicates on a single chip. After 13 min of hybridization at each cycle number, a 2 minute 
buffer step is added and is used to quantify Relative Shift values following hybridization. This is 
completed by subtracting the signal of control rings (Fig. 5.7A, blue trace) from the signal of 
target specific rings (Fig. 5.7A, red trace). The resulting calculated net shift induced by DNA 
binding is plotted versus the PCR cycle (Fig. 3B). In order to compare expression between 
samples, we follow similar qPCR quantification protocols and calculate a cycle threshold.
27
 This 
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is completed by determining the Relative Shift corresponding to 40% of the maximum signal of 
the amplification trace. At this Relative Shift threshold, we then determine at what cycle number 
the amplification crosses that threshold. Forty percent of the maximum signal was chosen 
because it is significantly above the noise of the baseline and is not prone to any errors when the 
amplification trace plateaus. This method also corrects any experimental or fabrication variations 
between microring arrays by not relying on a set Relative Shift threshold value.  
5.3.2 Demonstration in Clinically Relevant Samples 
After completing the optimization steps of the assay, we move to show the clinical utility 
of this platform by profiling the expression of multiple RNA sequences from multiple human 
derived samples, two commercially available pooled healthy RNA samples and RNA extracted 
from a glioblastoma cell line (GBM6). To ensure biological relevance, we chose lncRNAs that 
play important roles in the development or progression of brain cancer. KIAA0495/PDAM has 
been shown to act as a tumor suppressor in oligrodendrioglioma because of its activity blocking 
the expression of a p53 inhibitor.
28
 The other target, MALAT 1 (metastasis associated lung 
adenocarcinoma transcript 1), is a lncRNA that has been studied in different tumors.
29
 MALAT 1 
was first studied in NSCLC (non-small cell lung cancer cell) patients, and it was found that 
higher expression levels of MALAT1 occurred in those patients with metastasis.
30
 However, it 
has also been seen that MALAT1 can act as a tumor suppressor in glioblastoma.
31
 To correct 
from any sample processing variability we incorporate β-actin as an internal control.32 When 
analyzing these biological samples, we first measured lncRNA expression in different human 
tissues where minimal expression differences are expected (EMBL-EBI Expression atlas: 
MALAT1; EMBL-EBI Expression Atlas: TP73-AS1 (KIAA)).  After this validation step, we 
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aimed to analyze lncRNA expression in glioblastoma samples, where lncRNAs have been shown 
to be differentially expressed.
33
 
The amplification plots obtained from the three samples using the previously described 
method are shown in Figure 5.8. Additionally, the raw data used to compile these amplification 
profiles are plotted in Figure 5.9. The C(t) values were calculated as described in the previous 
section and can be seen in Table 5.3. To validate the results obtained with the microring 
resonator platform, the same RNA samples were profiled using qRT-PCR. The C(t) values 
obtained from this method are also shown in Table 5.3. The correlation of the results can be seen 
in Figure 5.10. Figure 5.10 represents the fold change in the expression of the transcripts in the 
cell line, GBM6, compared to the healthy brain reference and the differential expression between 
the two healthy tissues, brain and lung. The internal control, β-actin, was used to normalize the 
results and correct for initial input of RNA and other variabilities. Both techniques showed 
trends in the same direction, proving the consistency of our method. Additionally, we can further 
validate these results upon comparison with previously published studies in the literature, such as 
the downregulation of MALAT1 in glioblastoma samples.
31
 
5.4 Conclusions 
With this study, we demonstrate a promising approach for the multiplexed detection of 
long non coding RNAs. We have shown that the microring resonator platform combined with 
reverse transcription and asymmetric PCR is able to produce similar results as those obtained 
using the gold standard in transcript quantification, qRT-PCR. Using the described protocol, we 
were able to detect the differential expression of two lncRNAs. The introduction of an internal 
control allowed us the compare the expression among different samples. Additionally, this 
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platform decreased input amounts to clinically relevant levels, provides results within hours, and 
has the potential to analyze 32 RNA targets per sample. Future directions will include expanding 
multiplexing capabilities in lncRNA analysis, interrogating multiple cell lines to study role 
lncRNAs play in various cancer types, and interfacing thermocycling with microring detection 
using a single device. 
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5.5 Figures and Tables 
 
Figure 5.1: Assay schematic for microring resonator detection of long non coding RNAs.  
 
 
 
 
 
 
 
 
151 
 
 
Figure 5.2: Secondary structures of amplified regions obtained using the DinaMelt Web Server. 
The region that binds to the capture probe is highlighted with a red square. (A) β-actin amplified 
region will not bind to complimentary capture probes due to excessive secondary structure. (B) 
β-actin amplified region after primer redesign that enables surface binding. (C) KIAA0495 
amplified region with minimal secondary structure. (D) MALAT1 amplified region with minimal 
secondary structure. 
B 
D 
A 
C 
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Figure 5.3: Comparison of β-actin PCR product binding with and without optimized primer 
design.  The red trace shows improved binding when using the optimized primer sets (predicted 
structure shown in in Supplementary Figure 1B).  The black trace shows data obtained using the 
PCR amplicon with a high degree of secondary structure (Supplementary Figure 1A).   
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Figure 5.4: Agarose gel electrophoresis (2% agarose; SYBR Gold Stain) used to prove specific 
PCR amplification: (A) brain and lung RNA samples; (B) GBM6 cells RNA sample. Expected 
PCR product sizes are listed in red. 
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Figure 5.5: (A) Spotting layout of microring sensor chip. (B) Image of microring 
functionalization corresponding to the layout in Fig. 5.5A. 
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Figure 5.6: Cross-reactivity study used to determine the selectivity of the capture probes towards 
their specific target (A) KIAA0495, (B) MALAT1, and (C) β-actin. 
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Figure 5.7: (A) Detection of the β-actin aPCR product at different cycles using one microring 
resonator array. The chip was functionalized with either the specific transcript (red) or an off 
target (blue) DNA oligonucleotide capture probes. (B) Amplification curve for β-actin in healthy 
brain reference RNA.  The dotted lines outline the quantification process. 
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Figure 5.8: Amplification curves for the lncRNAs and internal control target (A) Healthy brain 
RNA, (B) Healthy Lung RNA, and (C) GBM 6 RNA 
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Figure 5.9: Microring traces used to calculate amplification plots in Figure 4. The trace signal 
represents the average from 8 – 16 ring replicates. 
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Figure 5.10: Comparison of fold changes using the microring resonator platform and 
quantitative PCR. Fold changes were calculated by normalizing to an internal control and 
comparing (A) lncRNA expression in GBM6 and healthy brain tissue and (B) the expression in 
lung and brain tissue.  
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Table 5.1: Primers used in the experiments for reverse transcription, asymmetric PCR and qRT-
PCR. Thermodynamic calculations were obtained from the Primer-Blast platform. 
 
 
 
 
 
 
 
 
 
 
Targeted transcript Sequence (5’  3’) Tm (° 
C) 
Amplicon 
length 
KIAA0495 
RP (RT 
primer) 
GCTGCTTGCTGTACGTGGTG 
62.18 
178 nt 
FP CGTGGCTGACACAAACTTGC 60.59 
CP /5AmMC12/GCTGCTTGCTGTACGTGGTG 
MALAT1 
RP (RT 
primer) 
GTGATGAAGGTAGCAGGCGG 
60.81 
150 nt 
FP ACATATTGCCGACCTCACGG 60.18 
CP /5AmMC12/GTGATGAAGGTAGCAGGCGG  
β-actin 
RP (RT 
primer) 
CATTCCAAATATGAGATGCGTT
GT 
58.18 
103 nt 
FP TGTGGACTTGGGAGAGGACT 59.81 
CP /5AmMC12/CATTCCAAATATGAGATGCGTTGT 
Off Target 
Control 
CP /5AmMC12/CTACAAGTGCCTTCACTGCAGT 
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Table 5.2: Fluidic handling protocol for the ring hybridization steps 
 
 
 
 
 
 
 
 
 
Step Flow Rate (μL/min) Duration (min) 
Hybridization buffer 20 5 
RT-PCR product cycle 30 20 13 
Hybridization buffer 20 2 
RT-PCR product cycle 32 20 13 
Hybridization buffer 20 2 
RT-PCR product cycle 34 20 13 
Hybridization buffer 20 2 
RT-PCR product cycle 36 20 13 
Hybridization buffer 20 2 
RT-PCR product cycle 38 20 13 
Hybridization buffer 20 2 
RT-PCR product cycle 40 20 13 
Hybridization buffer 20 5 
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RNA 
 
Target qRT-
PCR 
C(t) 
Rings 
C(t) 
qPCR Fold change 
(log(2))** 
Rings Fold change 
(log(2))** 
 
Brain 
Β actin 17.40 35.65 - - 
KIAA0495 21.16 33.09 - - 
MALAT1 17.77 33.04 - - 
 
Lung 
Β actin 17.40* 35.65* 0 0 
KIAA0495 21.57* 33.44* - 0.41 - 0.64 
MALAT1 16.38* 33.68* - 0.61 - 0.35 
 
GBM 6 
Β actin 17.40* 35.65* 0 0 
KIAA0495 21.36* 32.72* 0.20 0.32 
MALAT1 19.05* 34.90* -2.68 -1.81 
 
* Corrected signal with internal control 
** Healthy brain as reference; Fold Change = C(t)ref – C(t)sample 
Table 5.3: Calculated qRT-PCR and microring C(t) values from healthy brain, healthy lung and 
GBM6 RNA samples. The RNA input for qRT-PCR experiments was 40 ng, and the qRT-PCR 
experiments were completed in triplicate.   
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Chapter 6 
 
ADDITIONAL RESEARCH EFFORTS AND FUTURE 
DIRECTIONS 
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6.1 Additional Research Effort: Profiling Circulating miRNA Targets in Canine 
Osteosarcoma 
Canine osteosarcoma (OSA) patients have many biological and clinical similarities to 
human OSA patients, where it develops predominantly in children. Like children, OSA is the 
most common primary bone malignancy in dogs.
1
  While advances in treatment over the last 
several decades have pushed five year survival rates above 70%, pulmonary metastases are 
typically the cause of death in both humans and dogs.
2
  This, in combination with variable 
survival rates, suggests that OSA in both humans and canines exhibits variable metastatic 
capability, rate and/or resistance to chemotherapy.
3
  Additionally, these similarities have shown 
that canine patients serve as good models for human osteosarcoma,
4-6
 and that identifying 
biomarkers linking patients with likelihood of metastasis would help identify therapeutic 
decisions.  
 Recent studies have identified miRNA panels that are associated with OSA 
progression,
7,8
 prognosis,
9
 and chemotherapeutic response.
10
  However, a diagnostic test that 
determines the likelihood of metastasis is lacking in the clinic.  Given the success of miRNA 
panels to determine clinical outcomes, we have applied a similar assay to that listed in Chapters 
4-5 in an attempt to analyze profiles of circulating microRNAs found in patient’s blood that are 
predictive of OSA metastasis.  Circulating miRNAs are a promising class of miRNA that can be 
detected by a simple blood test.  This makes the resulting diagnostic test non-invasive and 
provides the ability to perform multiple blood draws to continuously monitor patients and 
determine the chance of metastasis in real time.   
 To complete this, a panel was developed using circulating miRNAs linked to OSA 
diagnosis
8
  as well as additional miRNA targets that have been linked to cancer metastasis.
9,10
  
The microRNA targets are listed in Table 6.1.  Next, blood samples were obtained from Prof. 
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Tim Fan (UIUC Veterinary Medicine).  Blood samples were collected every four weeks during 
the course of treatment.  This allowed for the longitudinal study of circulating biomarkers in the 
patient’s bloodstream.  Analysis of the time scale at which miRNA expression panels change and 
linking the changes of specific miRNA to metastasis onset could provide the missing link in 
OSA diagnostics. 
The blood samples were split into three cohorts, poor responders, good responders and 
healthy canine patients.  The poor responder cohort lived a maximum of 130 days after treatment 
started; whereas, the good responder cohort lived at least 237 days.  Healthy patient samples 
were profiled in an attempt to understand the underlying biomolecular signatures of canines.  It is 
important to note that both the poor responders and good responders eventually passed away due 
to metastasis to various tissues in the body. 
In order to detect circulating miRNA in these patient samples, we followed the following 
experimental protocol.  The miRNeasy Serum/Plasma Kit (Qiagen) was used to isolate 
circulating RNAs from blood samples.  It is important to avoid heparinized samples, as heparin 
is a PCR inhibitor.  After using UV-Vis spectroscopy, concentrations and RNA integrity were 
determined. RNA samples were then diluted in RNase-free water to 1 nanogram per microliter.  
Reverse transcription products were prepared using the TaqMan microRNA reverse 
Transcription Kit, and the recommended experimental protocol from the manufacturer was 
followed.  The final volume of all stem loop primers in the SLP mix was 200 μM.  After reverse 
transcription, asymmetric PCR was performed using the Platinum® Multiplex PCR Master Mix. 
Each 50 μL reaction volume was composed of 14 μL nuclease free water, 25 μL of Platinum® 
Multiplex PCR Master Mix, 5 μL of each primer and 1 μL of the reversed transcribed product. 
The concentration of the forward primer (the limiting primer) was 2 μM while the concentration 
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of the reverse primer was 200 μM. The reactions were incubated at 95 ºC for 2 min, followed by 
50 cycles of 95 ºC for 30 s, 56ºC for 1 min 30 s and 72 ºC for 1 min. 
The resulting PCR product was introduced to the microring chip at 20 μL per minute 
using the fluidic handling protocol listed in Table 6.2.  For this project, a new generation of the 
Maverick silicon photonic microring resonator platform was used.  This featured arrays of 12 
sensor chips that could be run sequentially and eliminates the needs to fabricate sensor cartridges 
for every experiment.  We incorporated an internal control, cel-39, to correct for any differences 
between runs.  This was completed by adding a fixed amount of the miR sequence before RNA 
extraction.  Since this should yield identical Relative Shift values upon ring quantification, any 
differences in this signal used to normalize the rest of the miRNA target Relative Shift values. 
In order to quantitate the data, a modified protocol to that presented in Chapters 4-5 was 
followed.  First, a calibration curve was prepared by preparing varying concentrations of miR-21 
and subjecting it through a fixed number of aPCR cycles.  This calibration curve was then used 
to determine the concentration of miRNA in the sample of interest, after normalizing to cel-39.  
This quantification protocol was followed before the updated version was developed.  It would 
be interesting to recollect this data using the updated quantification method. 
  The preliminary results for all patients can be seen in Figures 6.1-3.  Figure 6.1 shows 
the underlying biological variability in the RNA signatures of healthy patients.  It is apparent that 
there is some patient to patient variability, as Patients 1 and 2 have much higher expression 
levels compared to the others.  Figure 2 and 3 shows the comparison between data collected 
using the microring resonator platform and qRT-PCR for the poor and good responding cohorts, 
respectively.  Given the differing quantification protocols between the platforms, it is hard to 
directly compare the results, which is why overall magnitude and expression trajectories deviate 
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in some cases.  Additionally, there were no readily apparent expression changes that 
corresponded to cancer metastasis. 
 These results show the possibility to profile blood-based biomolecular profiles.  It also 
shows that there is a need for better predictive algorithms that can deconvolute changes in 
expression over time to aid in clinical decisions.  Additionally, there are improvements that can 
be made to the experimental design to help correct for underlying biological variability.  First, 
some of the miRNA targets were based on studies relating miRNA expression to OSA outcome 
in human samples.  We assumed that these findings would still be relevant in canines as well but 
this assumption has not yet been validated.  Second, using the improved quantitation protocol 
will increase the dynamic range of the sensing platform by effectively removing the baseline and 
plateau of the calibration curve.  This would allow for the direct comparison between qRT-PCR 
and the microring platform.  Third, there is no correction for canine breed or at what time point 
they are in disease progression.  Lastly, instead of just profiling multiple healthy patients at one 
time point, it would be interesting to first understand the temporal dynamics of circulating 
miRNA expression in healthy individuals before moving to diseased patients to see what moves 
are statistically significant. 
 
6.2 Conclusions and Future Work 
 The work presented in this dissertation lays the foundation to make multiplexed RNA 
measurements in clinical samples.  Moving forward, additional milestones will need to be 
reached.  Chapters 3-5 discussed the development and application of enzymatic processing 
strategies for RNA detection that provided lower sample input requirements, expanded dynamic 
ranges, and reduced assay times compared to previous lab attempts.  The aPCR assay presented 
in Chapters 4 and 5 provided better figures of merit, which makes it the scheme of choice for 
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future studies.  Future iterations of this this assay will need to focus on further automation, 
decreasing PCR reaction volume, and decreased time to result.  Additionally, after these assay 
improvements are made, further clinical utility will need to be determined. 
While Chapter 4 laid the foundation for the development of the aPCR assay for short 
RNA sequences, Chapter 5 not only translated this to longer RNAs but also lowered the aPCR 
processing time from over three minutes per cycle to under two minutes.   Further progress can 
be made here by further automating the system.  The main limitation currently is the PCR 
volume.  The current instrumentation needs approximately 300 microliters of solution to be able 
to flow long enough to get consistent hybridization curves.  Future efforts should aim to integrate 
microfluidic thermal cycling with the microring resonator array chip.  This will allow for the 
sample volumes to decrease as well as allow for the repeated cycling of the PCR product.  This 
will prevent the need for multiple aliquots of PCR samples, which makes the assay more cost 
effective and user friendly.  Second, by using a microfluidic approach, the thermal cycling speed 
can go much faster since less material needs to be heated and cooled.  This will then allow for 
the automated analysis of RNA molecules and make the transition to studying a higher number 
of samples more feasible. 
After device optimization is completed, different biological systems can be probed both 
in clinical and research settings.  In a clinical setting, we have started to make progress in 
diagnosing pathogenic infections based on RNA analysis.  This is a unique problem because 
sepsis is a leading cause of death in hospitals.  Diagnosis is of utmost importance to begin 
antibiotic therapy, as every hour of delay in administration of antibiotics is associated with an 
8% decrease in survival rate.
11
  Additionally, continuous reassessment is important, because 
inappropriate therapy deteriorates patient prognosis.
12 
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Given the importance of making rapid diagnosis and the need to continuously reassess 
patient biomolecular profiles, current clinical gold standards have their own shortcomings.  
Bacterial culture and biochemical staining have long procedural times (24-72 hours) and limitations in 
identifying certain species. Likewise, sequencing techniques are too expensive and time consuming for an 
everyday clinical setting.
13
  qPCR has sown particular promise in determining the pathogenic 
material based on unique 16S RNA sequences.  Using the asymmetric PCR-microring platform, 
initial studies have validated primer sets to detect specific pathogen species based on differences 
in the 16S RNA sequence of each pathogen.  The results are shown in Figure 6.4.  Future work 
will aim to expand out this panel to determine antibiotic resistance in these samples.  It is well 
documented that antibiotic resistant bacteria have evolved to obtain additional genes that lead to 
resistance of specific antibiotic therapies. In response to treatments, drug-resistant pathogens 
upregulate these genes, and yield the possibility to develop a biosensor to predict resistance.
14-16
 
After validation of antibiotic resistance determination, experiments in whole blood should be 
completed before profiling clinical samples. This finished product will be a two tier detection 
scheme where (1) infection determination based on 16S RNA target sequences and (2) antibiotic 
resistance determination based on dynamic changes to select genes. 
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6.3 Figures and Tables 
 
Overhang Forward Primer Sequence 
miR-21 tcaacatca CGCGCTAGCTTATCAGAC UAGCUUAUCAGACUGAUGUUGA 
miR-143 gagctacag GCGCGTGAGATGAAGCA UGAGAUGAAGCACUGUAGCUC 
miR-34a acaaccag CGTGGCAGTGTCTTAGC UGGCAGUGUCUUAGCUGGUUGU 
miR-150 cactggtac GCGTCTCCCAACCCTT UCUCCCAACCCUUGUACCAGUG 
miR-335 acatttttcg CGCGTCAAGAGCAATAACG UCAAGAGCAAUAACGAAAAAUGU 
miR-340 aatcagtct GCGCGCTTATAAAGCAATG UUAUAAAGCAAUGAGACUGAUU 
miR-544 gaacttgc GCGCGATTCTGCATTTTTA AUUCUGCAUUUUUAGCAAGUUC 
miR-199-
3p 
aaccaatgt GCGCACAGTAGTCTGC ACAGUAGUCUGCACAUUGGUU 
miR-140 tccgtgg GCGACCACAGGGTAGAA ACCACAGGGUAGAACCACGGA 
miR-132 gcgacca CGCTAACAGTCTACAGCCA UAACAGUCUACAGCCAUGGUCGC 
miR-34b caatcagc CGCGAGGCAGTGTAATTA AGGCAGUGUAAUUAGCUGAUUG 
miR-382  aaagtgttg CGCGAATCATTCACGGA AAUCAUUCACGGACAACACUUU 
cel-39 caagctga GCTCACCGGGTG TAAAT UCACCGGGUGUAAAUCAGCUUG 
 
 
Primer Sequence 
Reverse Primer GTGCAGGGTCCGAGGT 
Stem Loop 
Primer 
GTC GTA TCC AGT GCA GGG TCC GAG GTA TTC GCA CTG GAT 
ACG AC...overhang 
Capture Probes Identical sequence to forward primers with 5’ amino group modification 
 
Table 6.1: Table listing nucleic acid sequences used in the canine osteosarcoma study. 
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Step Flow Rate (μL/min) Duration (min) 
Hybridization buffer 20 5 
RT-PCR product 20 15 
Hybridization buffer 20 5 
 
Table 6.2: Summary of liquid handling steps 
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Figure 6.1: (A) Relative shifts obtained when profiling miRNA expression in the healthy patient 
cohort. (B) Calculated concentrations obtained after normalizing to cel-39. 
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Figure 6.2: (A and B) Comparison of Poor Responder 0 results obtained using the microring 
platform (A) and qRT-PCR (B).  (C and D) Comparison of Poor Responder 4 results obtained 
using the microring platform (C) and qRT-PCR (D). 
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Figure 6.3: (A and B) Comparison of Good Responder 1 results obtained using the microring 
platform (A) and qRT-PCR (B).  (C and D) Comparison of Good Responder 1 results obtained 
using the microring platform (C) and qRT-PCR (D). 
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Figure 6.4: Maximum signal achieved when determining specific pathogen types using the 
aPCR-microring platform.  This is an area of future work to be continued. 
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